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ABSTRACT 
Tang-Cheng Lee: Functional Analysis of EGFR Using a Conditional Allele 
(Under the direction of David Threadgill) 
 
 
 Epidermal growth factory receptor (EGFR) is a member of the ERBB family of 
tyrosine kinase receptors, which includes ERBB2, ERBB3 and ERBB4. EGFR signaling is 
complicated and involved in a variety of cellular processes, including proliferation, 
differentiation, migration, adhesion and anti-apoptosis.  
 EGFR has been studied using gene targeting to investigate the in vivo role of the 
receptor. Constitutional knockout of Egfr in mice results in placental defects with mice dying 
pre- or perinatally depending on the genetic backgroud. All Egfr null mice that survive to 
term eventually develop neurodegeneration that is primarily restricted to the cortex and 
olfactory bulb. Because the existing knockout models are unable to distinguish the cell 
lineage(s) (ie neuron, astrocyte or both) that depend on EGFR signaling for survival, and also 
result in pre- or peritnatal lethality limiting the ability to study the role of EGFR in 
physiological functions or diseases of adults in vivo, thus the generation of an Egfr 
conditional allele is necessary to overcome this limitation. Herein gene targeting was used in 
combination with the Cre/loxp system to generate an Egfr conditional allele. This allele was 
used to develop tissue-specific deletion of EGFR to explore its function in the central 
nervous system in order to understand the mechanism by which loss of EGFR results in 
neurodegeneration. 
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After the Egfr conditional allele (Egfrtm1Dwt) was generated, the Egfrtm1Dwt and Egfr∆, 
which is generated by Cre-mediated excision in the Egfrtm1Dwt, were characterized showing 
that the Egfrtm1Dwt possesses wildtype activity and can be inactivated tissue-specially, and the 
Egfr∆ is a null allele. 
To investigate the underlying mechanism responsible for neurodegeneration of Egfr 
null mice, three Cre transgenic lines expressed in the embryonic epiblast (Sox2-Cre) or 
neuroprogenitor cells (Nestin-Cre and hGFAP-Cre) were crossed with mice carrying the 
Egfrtm1Dwt conditional allele to generate Egfrtm1Dwt/tm1Dwt, Sox2-Cre (as well as Nestin-Cre or 
hGFAP-Cre) mice. Egfrtm1Dwt/tm1Dwt mice also carrying Sox2-Cre or Nestin-Cre displayed 
neurodegeneration in the cortex, olfactory bulb and areas surrounding lateral ventricle 
including corpus callosum, the fimbria of the hippocampus and subventricular zone (SVZ) 
and rostral extension (RE). These results were consistent with the phenotype of Egfr null 
mice. Conversely, Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice showed no damage within the brain. 
To locate differences in the distribution of Cre expression in the brain that leads to different 
phenotypes in the brain between Egfrtm1Dwt/tm1Dwt, Nestin-Cre and Egfrtm1Dwt/tm1Dwt, hGFAP-
Cre mice, Nestin-Cre and hGFAP-Cre mice were crossed with the ROSA26-lacZ reporter 
mice (R26R). Results indicated that the hGFAP-Cre line expresses Cre in the progenitors of 
the cortex, olfactory bulb, SVZ, RE and rostral migratory stream (RMS) but unlike Nestin-
Cre not the choroid plexus, despite the lack of neurodegeneration in Egfrtm1Dwt/tm1Dwt, 
hGFAP-Cre mice. These results suggest that neuronal or astrocytic death in the absence of 
EGFR signaling is a secondary effect, possibly mediated by the choroid plexus. 
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CHAPTER 1 
INTRODUCTION 
 
EGFR and ERBB family 
Epidermal growth factory receptor (EGFR) is a member of the ERBB family of 
tyrosine kinase receptors, which includes ERBB2, ERBB3 and ERBB4 (Fig.1-1). EGFR as 
well as other members are membrane-bound glycoproteins whose basic structure contains 
extracellular (including L1 [ligand-binding], CR1 [cysteine-rich], L2, and CR2 subdomains), 
transmembrane, juxtamembrane and kinase domains as well as a C-terminal tail with several 
tyrosine residues that can serve as docking sites after being phosphorylated. The active unit 
of ERBB receptors is a dimer or higher order oligomer. Upon ligand binding, ERBB 
receptors can form homo- or hetero-dimers with other members of the ERBB family. ERBB2 
is an orphan receptor that has no recognized ligand (Klapper et al., 1999), while ERBB3 
lacks kinase activity (Guy et al., 1994) due to the substitution of highly conserved residues in 
the kinase catalytic domain (Plowman et al., 1990), such that ERBB3 can only transmit 
signals through heterodimerization with other ERBB receptors. The formation of receptor 
dimers activates the intrinsic ERBB kinase activities, through trans-phosphorylation of 
tyrosine residues in the C-terminal tail of the receptors. Phosphotyrosines also serve as 
docking sites to recruit proteins containing SH2 or phosphotyrosine binding (PTB) domains 
that trigger intracellular signaling cascades. 
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EGFR ligands 
EGFR ligands include epidermal growth factor (EGF), transforming growth factor-α 
(TGFA), amphiregulin (AREG), diphtheria toxin receptor/heparin-binding EGF-like growth 
factor (DTR), epiregulin (EREG), betacellulin (BTC), and epigen (EPGN) (Fig.1-1). All 
EGFR ligands contain EGF-like domains with six spatially conserved cysteine residues (CX7 
CX4-5 CX10-13 CXCX8 C) that form three intramolecular disulfide bonds (C1-C3, C2-C4, 
C5-C6). This EGF-like domain is important for binding to ERBB receptors (Guy et al., 1994; 
Harris et al., 2003). The progenitors of the ligands are type 1 transmembrane proteins that are 
cleaved by ADAM (a disintegrin and metalloprotease) proteins to release mature growth 
factor ligands (Blobel, 2005). EGF was first discovered in the submaxillary gland of mouse, 
and it was found that EGF injection into newborn mice led to precocious eyelid opening and 
eruption of teeth (Cohen, 1962). Unexpectedly, EGF deficient mice do not display overt 
phenotypes of the hair or eyes, nor in other organs like lung, kidney and the gastrointestinal 
tract. Furthermore, Egf null mice are viable and fertile (Luetteke et al., 1999). However, EGF 
is a major accelerator of wound healing. Administration of EGF accelerates the healing of 
burn wounds on the skin of the Wistar rats, and attenuates tissue neutrophil accumulation 
(Jahovic et al., 2004). By contrast, Tgfa null mice exhibit wavy coats and curly whiskers, and 
dramatic derangement of hair follicles throughout the dermal layer. In addition, a number of 
Tgfa null mice display partial eyelid closure defects at birth, and exhibit clear corneal 
inflammation by five weeks of age (Mann et al., 1993). TGFA is also involved in blood 
vessel remodeling. Blood vessels are continuously subjected to dynamic mechanical forces, 
including stretch and shear stress. Those mechanical factors generate reactive oxygen species 
(ROS) that activate the transcription factor Nuclear Factor κB (NF-κB), which regulates both 
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blood vessel growth and the development and progression of vessel disease. TGFA/EGFR 
signaling is a mediator during the vascular process. Mechanical factor-induced ROS activates 
TGFA/EGFR signaling, which in turn activates downstream NF-κB signaling leading to 
vascular remodeling (Lemarie et al., 2006).  
Areg null mice do not display overt phenotypes. However female Areg null mice have 
an abnormal mammary gland phenotype (Luetteke et al., 1999). Virgin mice lacking AREG 
have underdeveloped mammary glands with less ductal outgrowth and branching. Pregnant 
and postpartum Areg null mice have abnormal lobuloalveolar development that affects milk 
production and impairs lactation resulting in perinatal morbidity of pups. AREG also protects 
against parasite infection. The immune response to nematode infection is primarily through 
T-helper 2 (TH2) lymphocytes and other cells secreting cytokines, including interleukin 4 
(IL-4), IL-5, IL-10, and IL-13. AREG is highly expressed in TH2 lymphocytes to enhance the 
clearance of nematodes from the mouse intestine (Zaiss et al., 2006). Unlike other EGFR 
ligands, DTR plays a more essential role in survival since it is important for normal heart 
development. Hearts from Dtr null mice have dilated and enlarged ventricular chambers with 
cardiomyocyte hypertrophy, and enlarged semilunar (aortic and pulmoic) and atrioventricular 
(mitral and tricuspid) valves (Iwamoto et al., 2003; Jackson et al., 2003). Like TGFA, DTR is 
also involved in the process of eyelid closure. DTR is expressed at the tips of two leading 
edges of the eyelid, and promotes epithelial cell migration through the EGFR-MAPK 
signaling pathway until the two leading edges of both eyelids meet and fuse at the center of 
eye (Mine et al., 2005).  
Ereg null mice exhibit no overt phenotypes. However, Ereg deficiency causes mice to 
be more susceptible to dextran sulfate sodium (DSS)-induced colitis (Lee et al., 2004). In 
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addition, Ereg null mice develop chronic dermatitis under specific pathogen-free (SPF) 
conditions that is mediated by non-bone-marrow-derived cells (Shirasawa et al., 2004). BTC 
has been implicated in pancreatic development. However, Btc null mice are viable and fertile, 
and in newborn Btc null mice, there are no morphological changes in pancreas. Adult Btc 
null mice also display normal expression of insulin, glucagon, cytokeratin and amylase 
(Jackson et al., 2003). Although BTC is not essential for pancreas development, an in vitro 
study has shown that BTC promotes beta cell differentiation (Thowfeequ et al., 2007). This 
result suggests a therapeutic potential for BTC against type 1 diabetes. EPGN is the most 
recently discovered EGFR ligand, having been cloned from a mouse keratinocyte cDNA 
library. EPGN expression is detected in mouse testis, liver and heart, and induces 
phosphorylation of MAPK (Strachan et al., 2001). 
 
EGFR signaling and biological function 
EGFR signaling is complicated and involved in a variety of cellular processes, 
including proliferation, differentiation, migration, adhesion and anti-apoptosis (Fig.1-2) 
(Yarden and Sliwkowski, 2001; Zaczek et al., 2005). For proliferation, one of the most 
important mitogenic pathways is the RAS-RAF-MEK-MAPK pathway. Activated EGFR 
recruits adapters such as SHC and GRB2 by using phosphotyrosine residues as docking sites 
in the C-terminal tail. GRB2-bound SOS, a guanylnucleotide exchange factor, activates RAS 
by changing GDP-bound RAS to GTP-bound RAS, triggering the intracellular signaling 
cascade. EGFR-activated MAPK pathway is involved in the progression of the cell cycle 
from G1 to S phase (Suhardja and Hoffman, 2003). Other important EGFR-activated 
pathways include PI3K/AKT and STAT pathways. In cerebral cortical cultures from mouse 
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brain, DTR promotes cell proliferation through the EGFR-activated PI3K/AKT pathway (Jin 
et al., 2005). The PI3K/AKT pathway is activated by EGFR not only in normal cell types but 
also in different cancer cells such as those from the prostate and esophagus. STAT proteins 
can be activated by direct binding to EGFR through their SH2 domain or can be activated 
through SRC proteins. EGFR-activated STAT pathways are involved in cell proliferation and 
survival of different types of solid tumors (Quesnelle et al., 2007).  
EGFR signaling is also required for cell differentiation as best exemplified in 
Drosophila eye development (Voas and Rebay, 2004). The Drosophila compound eye 
comprises about 750-800 individual units called ommatidia. Each ommatidia contains 20 
cells including eight photoreceptors (R1-R8), which collect visual inputs and transmit the 
stimuli to the optic lobes. Additionally, four cone cells secrete the lens and eight pigment 
cells optically insulate the individual ommatidia. During ommatidial development, EGFR 
signaling through the RAS/RAF/MEK/MAPK pathway provides the primary signal for 
recruitment all cells except R8 within ommatidia. R8 is the first cell recruited into the 
ommatidia in a process requiring the proneural gene Atonal. R8 secretes Spitz, the 
Drosophila ortholog of TGFA, to activate the EGFR signaling pathway within cells adjacent 
to R8, and results in recruitment of R2 and R5. By activating the EGFR signaling pathway, 
photoreceptors recruit more flanking cells into ommatidia as R3 and R4, then R1 and R6, and 
finally R7, as well as subsequent recruitment of cone and pigment cells.  
EGFR also prevents cell apoptosis and enhances cell survival through different 
downstream pathways. Many cancer cells overexpress EGFR and exert EGFR signaling 
pathways to escape chemotherapeutic drug- or radiation-induced apoptosis by upregulating 
anti-apoptotic proteins like BCL2 or BCLX, which block the release of cytochrome c from 
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mitochondria that is needed to induce a caspase-mediated cascade resulting in apoptosis. 
Similarly, EGFR can activate pathways that inhibit pro-apoptotic proteins like BAD, BAX, 
and BAK, which promote the release of cytochrome c from mitochondria causing apoptosis 
(Danielsen and Maihle, 2002). EGFR signaling can also promote cell migration, which is 
import for processes such as tumor invasion, wound healing and eyelid closure in newborn 
mice. Cell migration requires signals from the extracellular matrix (ECM) to activate 
receptor signaling pathways that induce the rearrangement of the actin cytoskeleton. One 
example is osteopontin, a secreted, intergrin-binding glycophosphoprotein that induces cell 
migration of mammary epithelial cells by activating EGFR and the downstream PLCγ/PKC 
pathway (Tuck et al., 2003). 
EGFR also crosstalks with integrins to mediate adhesion between cells and the ECM, 
which not only serves as a scaffold to stabilize the physical structure of tissues, but also is 
involved in regulating cell behaviors that can influence cell survival, differentiation, 
migration, proliferation, shape, and function. Upon integrin binding to the ECM, β-integrin 
binds to cytoskeletal proteins such as tailin and paxillin, which in turn recruit focal adhesion 
kinase (FAK) to activate downstream signaling cascades. Active FAK can also bind to EGFR 
and activate EGFR signaling (Miranti and Brugge, 2002). Another example of pathway 
crosstalk is between G-protein coupled receptor (GPCR) and EGFR signaling, where 
ADAMs play a role as a bridge. Upon agonist binding to GPCR, a signaling cascade is 
activated that causes some kinases (PKC, PYK2, SRC) or molecules (e.g. Ca2+, ROS) 
involved in the cascade to activate ADAMs, which in turn, result in ectodomain shedding of 
growth factor progenitors and release of active growth factor ligands that bind and activate 
EGFR (Ohtsu et al., 2006). Less well understood are results that suggest EGFR can 
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translocate to the nucleus directly, although the nuclear EGFR pathway is similar to 
traditional pathways in regulating gene expression and mediating cellular processes (Lo and 
Hung, 2006).  
 
Endocytosis and degradation of EGFR 
Once activated membrane-bound receptors are usually destined for lysosomal 
degradation through receptor endocyosis, a process of protein sorting and internalization 
from the cell membrane. Other than basal endocytosis or nonclathrin-mediated endocytosis, 
ligand-induced and clathrin-mediated EGFR endocytosis has attracted the most investigation. 
Growth factor-induced EGFR endocytosis requires activation of EGFR, thus also providing a 
way to downregulate receptor activity. During the process of EGFR endocytosis, 
monoubiquitination of EGFR is a critical step since ubiquitin functions as a signal for protein 
sorting (Fig. 1-3) (Haglund et al., 2003; Le Roy and Wrana, 2005; Williams and Urbe, 2007). 
Upon EGFR activation, phosphorylated EGFR recruits and phosphorylates CBL, an E3 
ubiqiutin ligase, which in turn ubiquitylates activated EGFR. Phosphorylated CBL will 
interact with CIN85 (CBL interacting protein of 85 kDa) and CIN85 in turn binds to 
endophilin, which is regulatory component of clathrin-coated pits that can bind to lipid 
bilayers and induce local changes in membrane curvature. Activated EGFR also 
phophorylates clathrin and EPS15 (EGFR pathway substrate 15) and Epsin. Phosphorylation 
of clathrin causes its redistribution at the cell periphery and EPS15 as well as Epsin 
recognize ubiquitylated EGFR by their ubiquitin-interacting motifs (UIMs). Epsin also 
interacts with clathrin and clathrin adapter protein AP2. EPS15 and Epsin are critical 
components for the internalization of EGFR from cell membranes. At the early endosome 
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stage, EGFR is either recycled back to the cell surface or is sorted into multivesicular 
endosome/multivesicular body (MVE/MVB). Also at the early endosome stage, a UIM-
containing protein, HRS (hepatocyte growth factor-regulated tyrosine kinase substrate) 
complexes with two other UIM-containing proteins, EPS15 and STAM (signal transduction 
adapter molecule) to sort cargo like EGFR to the ESCRT-I complex (endosomal sorting 
complex required to transport-I). In the HRS-STAM-EPS15 complex, both HRS and EPS15 
bind to multiply ubiquitylated EGFR, and importantly, those UIM-containing proteins 
themselves are also ubiquitylated by ubiquitin ligase. Thus, EPS15 can regulate 
intramolecular interactions between its own UIM and ubiquitin, and dissociate from 
ubiquitylated EGFR to transfer EGFR to HRS. Using the same mechanism, HRS sorts EGFR 
into MVE/MVB through an interaction with another UIM-containing protein, TSG101 
(tumor susceptibility gene 101), another component of the ESCRT-I complex. Subsequently, 
EGFR is transported from ESCRT-I to ESCRT-II then ESCRT-III, before finally being 
sorted into intralumenal vesicles of MVE/MVB that are formed through invagination and 
pinching-off the endosome membrane. Eventually, MVE/MVB fuses with the lysosome, 
resulting in degradation of EGFR by lysosomal acidic hydrolases.  
   
EGFR and disease 
EGFR mutations and EGFR-mediated signaling pathways are involved in the 
development of many diseases. It is well known that EGFR is overexpressed in different 
types of cancer including those of the lung, colon, head and neck, prostate, breast, ovary, 
stomach, esophagous and glia. Many cancer cells use the EGFR signaling pathway for cell 
proliferation, survival, and even metastasis. In non-small-cell lung cancer (NSCLC), EGFR 
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mutations occur in exons 18-21, which codes for the tyrosine kinase domain. Exon 19 
deletions account for 44% of EGFR mutations in NSCLC, while the single nucleotide 
substitution L858R in exon 21 for 41%, the in-frame insertion in exon 20 for 5%, and other 
point mutations in exons 18-21 for 10% (Shigematsu and Gazdar, 2006). The exon 19 
deletion and single nucleotide substitution L858R in exon 21 of EGFR codes for receptors 
that increase the magnitude and duration of signal activation compared with wildtype 
receptors. Cancer cells that possess these EGFR mutations are more sensitive to tyrosine 
kinase inhibitors, such as gefitinib and erlotinib. Another EGFR mutation, the variant III 
EGFR deletion (EGFRvIII) is commonly observed in glioma, and has been reported to occur 
in other types of cancer such as those of the prostate, breast, ovary and stomach. EGFRvIII is 
an in-frame deletion encompassing part of the extracellular domain of EGFR and ablating its 
ligand-binding ability, resulting in constitutive activation of EGFR. Since EGFRvIII appears 
in several different types of cancer, it has been proposed as a prognostic and therapeutic 
target (Nicholas et al., 2006).  
The ApcMin mouse model for colorectal cancer has shown that intestinal adenoma 
multiplicity relies on EGFR signaling; reduction of EGFR activity significantly decreases 
polyp number (Roberts et al., 2002). About 60-80% of colorectal cancers express EGFR, 
which may be associated with response to radiotherapy, adverse prognosis and shorter 
survival time (Zlobec et al., 2007). This has caused EGFR to be a therapeutic target for 
colorectal cancer.  
EGFR is connected to other diseases as well. Psoriasis is a skin disease characterized 
by epidermal hyperproliferation, disturbed differentiation, inflammation, excessive dermal 
angiogenesis and abnormal keratinization. EGFR and its ligands, EGF as well as TGFA have 
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been indicated to be significantly increased in psoriatic epidermis and keratinocytes (Ben-
Bassat and Klein, 2000). EGFR activation also contributes to angiotensin-II-induced 
hypertension, cardiac hypertrophy, atherosclerosis, and kidney disease (Shah and Catt, 2003, 
2006). Angiotensin II is the dominant effector of the renin-angiotensin system (RAS), which 
has an important physiological role in the regulation of blood pressure and aldosterone 
secretion. However, overactivity of RAS can result in renal disease and disorders of the 
cardiovascular system. The mechanism by which angiotensin II leads to disease is through 
the transactivation of EGFR that is mediated by ADAMs. Angiotensin II is a peptide 
hormone that binds to the AT1 receptor, which is a GPCR that activates downstream 
molecules PLC and PLC that in turn activate kinases such as PKC, SRC, PYK2, increasing 
the release of Ca2+ and ROS. Activation of PKC, SRC, and PYK2 or release of Ca2+ and 
ROS can induce ADAM activity resulting in ectodomain shedding of DTR and TGFA, 
leading to activation of EGFR signaling. In the heart, elevated EGFR signaling can cause 
cardiac hypertrophy and fibroblast proliferation and in the kidney, renal lesions by promoting 
cell proliferation, mesenchymal epithelial transdifferentiation, collagen production, matrix 
deposition and glomerulosclerosis.  
Menetrier’s disease is a stomach disease characterized by selective expansion of 
surface mucous cells in the body and fundus of the stomach (Coffey et al., 2007). The 
symptoms of this disease include abdominal pain, nausea, vomiting, anemia (due to gastric 
blood lose), hypochlorhydria (due to markedly reduced numbers of parietal cells), and edema 
of peripheral tissues (due to leakage of protein across the gastric mucosa). It is believed that 
Menetrier’s disease results from the elevated EGFR signaling in the gastric mucosa caused 
by local overproduction of TGFA; patients with Menetrier’s disease exhibit enhanced 
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immunoreactivity of TGFA in the expanded surface mucous cell compartment. Transgenic 
mice overexpressing TGFA in the stomach display phenotypes similar to Menetrier’s disease. 
As EGFR is widely expressed in different organs and tissues, and the EGFR signaling 
network is involved in many cellular processes, it is not surprising that homeostasis of EGFR 
signaling is important for developmental processes and physiological functions. Lack or 
overproduction of EGFR signaling results in developmental defects or abnormalities of 
physiological functions. 
EGFR has been studied using gene targeting to investigate the in vivo role of the 
receptor. Constitutional knockout of Egfr in mice results in placental defects with mice dying 
pre- or perinatally depending on the genetic background (Sibilia and Wagner, 1995; 
Threadgill et al., 1995). All Egfr null mice that survive to term eventually develop 
neurodegeneration that is primarily restricted to the cortex and olfactory bulb.  The placental 
defect in Egfr null mice can be rescued in chimeras generated by aggregation of 2N Egfr-/- 
zygotes with 4N wildtype embryos or ES cells, where the 4N cells contribute entirely to 
extraembryonic tissues including the placenta. However, Egfr null chimeras that have a 
normal placenta also develop neurodegeneration after birth and die within one month of 
birth. The existing models cannot distinguish the cell lineage(s) (ie neuron, astrocyte or both) 
that depend on EGFR signaling for survival. In addition, the current models result in pre- or 
postnatal lethality limiting the ability to study the role of EGFR in physiological functions or 
diseases of adults in vivo. Thus, the generation of an Egfr conditional allele is necessary to 
overcome this limitation. Herein gene targeting was used in combination with the Cre/loxp 
system to generate an Egfr conditional allele. This allele was used to develop tissue-specific 
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deletion of EGFR to explore its function in the central nervous system in order to understand 
the mechanism by which loss of EGFR results in neurodegeneration.  
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Fig. 1-1 The structure of EGFR and other ERBB receptors and their ligands. EGFR 
and other ERBB receptors contain an extracellular domain (including two ligand-
binding domains and two cysteine-rich domains), a transmembrane domain, a 
juxtamembrane region, a kinase domain, and a C-terminal tail. Progenitor lignads of 
EGFR are membrane-bound proteins containing EGF-like domain(s), some with an 
additional heparin-binding domain. Modified from (Harris et al., 2003) 
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Fig. 1-2 Layers of the EGFR signaling network. (A) The input layer represents the 
lignad binding and activation of EGFR. (B) The signal processing layer is where EGFR 
triggers different downstream signaling pathways including RAS/RAF/MEK/MAPK, 
PI3K/AKT, PLCγ/PKC among other pathways. (C) The output layer is the results of 
EGFR signaling, which eventually induces distinct cellular events including 
proliferation, anti-apoptosis, differentiation, migration and adhesion. Modified from 
(Yarden and Sliwkowski, 2001) 
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Fig. 1-3 EGFR endocytosis. Upon ligand stimulation, activated EGFR recruits and 
phosphorylates CBL, which in turn multiubiquitylates EGFR and associates CIN85 and 
endophilin. Ubiquitylated EGFR recruits ubiquitin receptors, EPS15 and Epsin, the latter of 
which interacts with clathrin and AP2. After EGFR is sorted into early endosomes, EPS15 
complexes with two other ubiquitin receptors, HRS and STAM and dissociates from 
ubiquitylated EGFR. From the early endosome, ubiquitylated EGFR can be either recycled 
to cell membrane or sorted into MVE/MVB through the interaction between HRS and the 
ESCRT-I complex. Ubiquitylated EGFR targeted for degradation is transported to ESCRT-
II, ESCRT-III, and then to intralumenal vesicles. The MVE/MVB fuses with the lysosome 
resulting in degradation of EGFR by lysosomal acidic hydrolases. Modified from (Le Roy 
and Wrana, 2005) 
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CHAPTER 2 
GENERATION OF GERMLINE CHIMERAS 
 
Abstract 
In order to investigate the tissue-specific function of Egfr, a conditional knockout 
mouse model was produced. The first two constructs engineered did not produce any targeted 
events or targeted Egfr at a very low frequency. The third construct was designed with much 
longer homologous regions, resulting in a greater targeting efficiency than the previous two 
constructs. The third construct resulted in 13 targeted embryonic stem (ES) cell clones out of 
300 screened clones. Southern blot and PCR analyses confirmed that among the 13 targeted 
clones, 11 clones had the predicted genomic organization after targeting. Two of the 11 
targeted clones were chosen to prepare for microinjection and then producing chimeras. First, 
Cre recombinase was transiently expressed in the targeted ES cells to remove the neo 
cassette, followed by RT-PCR to confirm that two remaining loxp sites in the targeted Egfr 
gene did not alter the RNA splcing pattern. Subsequently, the targeted ES cells were 
microinjected into blastocysts from CD1 mice, and four chimeras were generated, all with 
low coat color chimerism. Of the four chimeras, one was sterile and the others were fertile. 
The fertile chimeras, however, did not transmit the modified allele to any progeny within the 
first ten litters produced. Consequently, the targeted ES cells were used for microinjection 
into blastocysts from C57BL/6 mice to generate chimeras; the modified allele was found in 
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the progeny of these chimeras, and a colony of mice carrying the Egfr condtional allele 
established for functional studies. 
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Introduction 
Gene targeting technique is frequently used to generated knockout or null alleles for 
creating mouse models lacking specific genes. In this way, the function of individual genes 
can be determined in vivo through careful phenotypic analysis. Thus, gene targeting provides 
a powerful tool for gene function studies. Mice that are deficient for specific genes can show 
phenotypes from early embryonic stages through adults. Deletion of some genes will result in 
no phenotype or an undetectable phenotype due to genetic redundancy or compensation by 
other genes or the lack of appropriate physiological stress. It is also very common that genes 
may play multiple roles in different tissues or organs, or at different stages of development. 
In particular, embryonic lethality will prevent the study of postnatal or adult physiological 
functions. In order to overcome the limitation of embryonic lethality, conditional alleles are 
commonly generated that allow the deletion of specific genes to be controlled spatially and 
temporally. 
Studies have shown that homozygosity for targeted mutations in any member of the 
Erbb family of receptor tyrosine kinases results in embryonic lethality. Egfr deficient mice 
die prenatally from placental abnormalities or perinatally with abnormalities in skin, lung, 
brain and gastrointestinal tract depending on genetic background (Miettinen et al., 1995; 
Sibilia and Wagner, 1995; Threadgill et al., 1995). Embryos homozygous for a null mutation 
in Erbb2 die before embryonic day (E) 11 with defects in cardiac trabeculation and impaired 
neural development (Lee et al., 1995). Deficiency for Erbb3 causes mid-gestation lethality 
from abnormal cardiac cushion development and a lack of Schwann cell precursors, which in 
turn results in degeneration of the peripheral nervous system and death of motor and sensory 
neurons in the dorsal root ganglia owing to a lack of neurotrophic factors provided by 
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developing Schwann cells (Lee et al., 1995; Riethmacher et al., 1997). Erbb4 mutant 
embryos die at E10-11 due to the failure of trabeculation in the heart ventricle, which is 
similar to the phenotype in Erbb2 null mice. ErbB4 deficiency also results in abnormal 
development of the hindbrain leading to mis-innervation (Gassmann et al., 1995). 
Since embryonic lethality limits studies of post-natal phenotypes for all members of 
the Erbb gene family, including Egfr, it is necessary to create conditional mutations to 
selectively remove the genes from specific tissues. Although conditional alleles have been 
generated for Erbb2, Erbb3 and Erbb4 (Crone et al., 2002; Fitch et al., 2003; Garcia-Rivello 
et al., 2005; Long et al., 2003; Qu et al., 2006), there are no available Egfr conditional 
knockout mouse models. In this study, an Egfr conditional knockout mouse model was 
generated using the Cre/loxp system (Lewandoski, 2001; Nagy, 2000). Cre is a 38-KDa 
monomeric protein encoded by bacteriaphage P1 (Abremski and Hoess, 1984), while Loxp is 
a 34-bp sequence consisting of two 13-bp inverted repeats and an 8-bp asymmetric core 
sequence, which provides directionality. Cre cooperatively binds to loxp sites with one Cre 
monomer contacting each of 13-bp inverted repeats. Association of two dimers of Cre on 
each loxp site forms a synaptic structure and catalyzes recombination between two loxp sites 
(Ghosh and Van Duyne, 2002). Cre-mediated loxp recombinations include 
excision/integration, inversion and translocation depending on the alignment and direction of 
two loxp sites (Fig.2-1) (Kwan, 2002; Nagy, 2000). The general strategy used to develop a 
conditional knockout mouse model for Egfr includes several steps: (a) construction of a 
targeting vector. (b) identification of targeted ES cell clones. (c) removal of the neo selection 
cassette. (d) microinjection of targeted ES cells into blastocysts. (e) transfer of blastocysts 
into uteri of psedopregnant recipients. (f) generation of chimeras. (g) germline transmission 
 24 
of the modified alleles (Fig. 2-2). In this chapter, the development of an Egfr conditional 
knockout mouse model is presented.    
  
Materials and methods 
Construction of targeting vectors 
Vector 1 and Vector 2 
For constructing vectors 1 and 2, clone 158K10, containing the Egfr locus was isolated from 
the RPCI-22 129S6/SvEvTAC BAC library (BacPac Resources, Children’s Hospital Oakland 
Research Institute), and was used as a template to amplify DNA fragments of Egfr. 
Construction of vector 1 began with the ligation of a 1.3 kb PCR fragment containing part of 
first intron into pCR2.1-TOPO to serve as the 5’ homologous region. A neo cassette flanked 
by two loxp sites that includes unique Cla1 and a Sal1 sites was inserted into the Xho1 site of 
pCR2.1-TOPO. Subsequently, a 4.0 kb fragment consisting of a loxp site, part of first intron, 
exons 2-4, and part of fourth intron was inserted into Cla1 site. Finally, a 5.0 kb fragment 
containing part of intron 4, exon 5, intron 5 as well as part of exon 6 was inserted into Sal1 
site to serve as the 3’ homologous region. Vector 2 was similar to vector 1 except with a 2.6 
kb 5’ homologous region rather than 1.3 kb as in vector 1. 
Vector 3 
 Because of the targeting inefficiency of vectors 1 and 2, vector 3 was designed to 
have longer homologous regions. BAC clone 158K10 was cut with EcoR1 to obtain two 
DNA fragments of 6.0 kb and 12.8 kb, respectively. The 6.0 kb EcoR1 fragment was further 
cut with Nhe1 to produce a 4.3 kb EcoR1-Nhe1 fragment that was inserted into plox-neo-lox 
as the 5’ homologous region. The remaining 1.7 kb Nhe1-EcoR1 fragment was ligated with a 
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7.5 kb EcoR1-Xma1 fragment that was generated from the 12.8 kb EcoR1 fragment cut with 
Xma1. After subcloning this 9.2 kb Nhe1-Xma1 fragment, a loxp site was inserted into the 
Spe1 site within intron 3 before cloning this fragment into plox-neo-lox to complete vector 3. 
ES cell culture 
The TL1 ES cells, derived from 129S6/SvEvTAC were a gift from Dr. Brigid Hogan (Duke 
University). ES cells were cultured in Dulbecco’s modified eagle medium (DMEM) (Gibco-
BRL), with 15% heat-inactivated fetal bovine serum (FBS) (Gibco-BRL), 2mM L-glutamine 
(Gibco-BRL), 0.1mM non-essential amino acids solution (Gibco-BRL), 50 units/ml 
penicillin-50 µg/ml streptomycin (Gibco-BRL), 0.1mM 2-mercaptoethanol (Sigma), as well 
as 1000 units/ml ESGRO (murine leukemia inhibitory factor; Gibco-BRL). For selecting 
neomycin-resistant ES cell clones, the ES cell medium were supplemented with Geneticin 
selective antibiotic (G418) (Gibco-BRL) at 200 µg/ml. 
Electroporation 
Cultured ES cells were trypsinized, washed once with phosphate-buffered saline (PBS) and 
resuspended as a single cell suspension at a concentration of 1 × 107 cells/ml in Ca2+/Mg2+-
free PBS. For electroporation, 0.8 ml of cells were placed in a 0.4 cm wide curvette, and 
mixed with 10 µg of linearized targeting vector. The cuvette was set at room temperature for 
5 minutes before applying a 240 V, 500 µF pulse to the cells using a Gene Pulser II (Bio-
Rad). After electroporation, the ES cells were cultured in ES cell medium with 200 µg/ml 
G418.  
Colony picking 
G418-resistent ES cell colonies were picked and cultured in 96-well plates. When ES cells 
reached confluency, they were passaged into two plates. An equal volume of 2X freezing 
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medium (DMEM with 40% FBS and 20% dimethylsulfoxide [DMSO]) to each well of one 
plate before topping with 100 µl of sterile light paraffin oil. This plate was placed in a 
styroform box, stored at -70°C for at least 24 hours, and then transferred to liquid nitrogen 
for long-term storage. The cells in second other plate were further grown to confluency for 
analysis. 
Molecular analysis of ES cell clones 
ES cells were washed twice with PBS and 50 µl of lysis buffer (10 mM Tris [pH 7.7], 10 mM 
ethylenediamine tetraaceticacid [EDTA], 10 mM NaCl, 0.5% sarcosyl, and fresh-prepared 1 
mg/ml proteinase K) was added to each well. The plate was then placed in a Tupperware-
type container with wet towels and incubated at 60°C oven overnight. The next day, 100 µl 
of precipitation solution (150 µl of 5 M NaCl to 10 ml of cold absolute ethanol) was added to 
each well. The plate sat at room temperature for 30 minutes before discarding the solution by 
inversion of the plate. The precipitated genomic DNA remained on the bottom of the wells. 
Each well was washed three times with 70% of ethanol before drying the genomic DNA. 
Finally, 30 µl of restriction digestion mixture containing 10 units of PflF1, EcoN1 or Nde1 
was added to each well and incubated at 37°C overnight.  
Digested genomic DNA was subjected to agarose gel electrophoresis, and afterwards, 
the gel was soaked in denaturation solution (0.4M NaOH, 3M NaCl). The restriction 
fragments were transferred from the agarose gel to a nylon transfer membrane (Schleicher & 
Schuell, Nytran supercharge). After UV crosslinking the transferred DNA to the membrane, 
a 1.3 kb 32P labeled probe from upstream of the 5’ homologous region of targeting vector 
was hybridized overnight to detect targeted and wildtype alleles. The membrane was washed 
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and then exposed to X-ray film to detect the hybridized bands, which corresponded to a 6.9 
kb PflF1 fragment for targeted allele and a 9.4 kb fragment for the wildtype allele.  
Transient expression of Cre and removal of the neo cassette 
To remove the neo cassette, correctly targeted ES cells were electroporated with 5 µg 
pCMV-Cre vector containing Cre driven by a human cytomegarovirus major immediate 
early promoter (CMV promoter). The procedures of electroporation and genomic DNA 
extraction were identical to those used to generate the targeted ES cells clones. The genomic 
DNA from each colony was subjected to PCR screening to identify colonies with an 
appropriately removed neo cassette. 
PCR genotyping 
To determine whether the third loxp site was present in the 13 targeted ES cell clones, 
genomic DNA was amplified for 35 cycles (30 s at 94°C, 1 min at 60°C and 1 min at 72°C) 
using Taq DNA polymerase (Qiagen) and a GeneAmp PCR system 9700 (Applied 
Biosystems). The primers were lox3s 5’-CTTTGGAGAACCTGCAGATC-3’ and lox3as 5’-
CTGCTACTGGCTCAAGTTTC-3’. A 375 bp PCR product resulted if the third loxp site was 
present, while a 320 bp PCR product was generated if the loxp site was not present.  
To screen ES cell clones after Cre-mediated partial loxp recombination, genomic 
DNA from each ES cell colony was amplified for 35 cycles (30 s at 94°C, 1 min at 60°C and 
1 min at 72°C). The primers were CTE-1 5’-CCAGGGACTACCAGTGGGTT-3’ and CTE-2 
5’-GAGGTGGCTCCTAATGGCTT-3’. The flox specific band was 431 bp and the wildtype 
band was 336 bp. 
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Reverse transcriptase-polymerase chain reaction (RT-PCR) 
To determine whether loxp sites within introns affect Egfr expression or spicing, RT-PCR 
was performed. Total mRNA was extracted from targeted and wildtype ES cell clones using 
TRizol reagent (Invitrogen) according to manufacturer’s instructions. The targeted or 
wildtype ES cells were mixed with TRizol reagent (5-10 × 105 cells/ml) and repetitively 
pipeted to lyse the cells. For each ml of Trizol reagent, 0.2 ml of chloroform was then added. 
After centrifugation (12,000 ×g, 15 min), the upper aqueous phase was removed to a fresh 
tube and isopropyl alcohol was added (TRizol : isopropyl = 1 : 2) to precipitate RNA. The 
RNA was pelleted by centrifugation (12.000 ×g, 10 min) and the pellet washed once with 
70% ethanol before drying briefly. Finally, the RNA was dissolved in RNase-free water. One 
µg of mRNA was used as template for synthesis of cDNA using random primers (Gibco-
BRL) and SuperScript II RT (Gibco-BRL) in a total reaction volume of 20 µl. The cDNA 
was used as template for PCR amplification of exons 2-4 for 35 cycles (30 s at 93°C, 1 min 
at 58°C and 1 min at 72 °C). The primers were RNA2 5’-TGCCAAGGCACAAGTAACAG-
3’ and RNA4 5’-GCTCGGATGGCTCTGTAAGT-3’. The predicted wildtype band was 465 
bp. 
Microinjection, uterine transfer and chimera generation 
Blastocysts were prepared by flushing the uteri of 3.5 days postcoitum (dpc) pregnant CD1 
females with M2 medium (Chemicon). Approximately 10-15 targeted ES cells in KSOM 
medium (Chemicon) were microinjected into each blastocyst. ES cell-injected blastocysts 
were then transferred into the uteri of 2.5 d.p.c. pseudopregnant recipient CD1 females that 
had been mated with vasectomized males. The ES cell-injected chimeras were easily 
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differentiated by two coat colors, one derived from the albino CD1 blastocysts and the other 
derived from agouti ES cells. 
 
Results 
Construction of targeting vectors 
 To generate an Egfr conditional allele, a Cre-loxp strategy was employed. Two 
vectors were designed to inactivate Egfr by Cre-mediated excision of a loxp-flanked region 
including exons 2-4, which encodes an essential part of the EGFR ligand-binding domain. 
Vector 2 has longer 5’ homologous arm compared to vector 1 (2.6 kb vs 1.3 kb), and both 
have the same 3’ homologous arm (5.0 kb). Instead of disrupting Egfr by deleting exons 2-4 
as planned for vectors 1 and 2, vector 3 was designed to inactivate Egfr by deleting exon 3, 
which would introduce a frameshift in the reading frame after Cre-mediated excision. Vector 
3 also has much longer 5’ and 3’ homologous regions (4.3 kb and 8.4 kb, respectively), and 
is expected to have higher targeting efficiency than vectors 1 and 2 (Fig. 2-3). 
 
Targeting efficiency and targeted ES cell clones 
 One thousand G418-resistant ES cell clones from an electroporation with vector 1 
were screened by Southern blot analysis, but no targeted clone was obtained. For vector 2 
electroporated ES cells, 300 ES cell clones were screened and only one was correctly 
targeted. As anticipated, vector 3 had a much higher targeting efficiency, resulting in 13 
targeted ES cell clones out of 300 G418-resistant ES cell clones (Table 2-1). The targeted 
allele was identified as a 6.9 kb PflF1 fragment by Southern blot analysis as opposed to the 
wildtype allele that was a 9.4 kb fragment. All 13 targeted ES cell clones were subjected to 
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further confirmation. One of the 13 targeted clones had lost the third loxp site as determined 
by PCR screening, indicating that in this clone homologous recombination occurred in the 
region between the second and the third loxp sites. Another clone contained a correctly 
targeted allele but the other allele differed from the predicted wildtype allele. The remaining 
11 ES cell clones were correctly targeted clones (Fig. 2-4). 
 
 
 
 Number of ES cell 
clones screened 
Number of targeted 
ES cell clones 
Percentage of targeted 
ES cell clone (%) 
Vector 1 1000 0 0 
Vector 2 300 1 0.33 
Vector 3 300 13 4.33 
 
 
Removal of neo cassette by transient Cre expression 
 Based on colony morphology and karyotyping, two clones were chosen for further 
preparation. Considering that the selectable neo cassette may influence the expression of the 
targeted allele (Fiering et al., 1995; Meyers et al., 1998), Cre was transiently expressed to 
remove the neo cassette by partial loxp recombination between the first and the second loxp 
sites, thus, removing the neo cassette but retaining two loxp sites in the targeted allele 
franking a region including exon 3. Two primers were designed, one located upstream of the 
first loxp site and the other located in the region between the second and the third loxp sites 
Table 2-1 Targeting frequencies  
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(Fig. 2-5A). PCR was performed to screen the ES cell colonies, and several clones were 
identified that had partial recombination occurring between the first and the second loxp sites 
as indicated by a 431 bp PCR product. Most ES colonies underwent complete recombination 
that excised not only the neo cassette but also exon 3 (Fig. 2-5B). The allele that possesses 
two loxp sites flanking exon 3 was called the Egfrtm1Dwt allele, while the allele with complete 
loxp recombination as the Egfr∆ allele (Fig. 2-6).  
 
Insertions of loxp sites do not alter Egfr splicing  
 To examine if the insertions of loxp sites in Egfrtm1Dwt disturb gene expression or alter 
splicing, RT-PCR analysis was conducted. RNA extracted from wildtype ES cells and 
targeted ES cells containing the Egfrtm1Dwt allele was used as template, and primers were 
designed to be located in exons 2 and 4. The resulting RT-PCR product amplified from the 
Egfrtm1Dwt allele was identical in size and quantity to that from the wildtype allele, suggesting 
that insertions of loxp sites in the Egfrtm1Dwt allele do not alter the splicing pattern or reduce 
gene expression (Fig. 2-7). This result suggests that the Egfrtm1Dwt allele should function as a 
wildtype allele.  
 
Generation of chimeras 
 To generate chimeras, 10-15 ES cells carrying the Egfrtm1Dwt allele were injected into 
3.5 d.p.c. blastocysts from CD1 mice, and the injected blastocysts were transferred into the 
uteri of 2.5 d.p.c. pseudopregnant CD1 recipients. Four chimeras with low coat color 
chimerism (5-30%) were generated and mated with wildtype female CD1 mice (Fig. 2-8). 
Germline transmission was not obtained from any of the CD1 chimeras. A second round of 
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chimeras was produced by injection of targeted ES cells into C57BL/6 blastocysts. Ten 
chimeras were obtained, all with much higher coat color chimerism (45-100%) than with 
CD1 chimeras. Five high contribution male chimeras (85-100%) were chosen to mate with 
wildtype C57BL/6 and 129SvEv females, which produced agouti pups containing the 
Egfrtm1Dwt allele as determined by PCR. The pups carrying Egfrtm1Dwt allele will be used for 
functional studies of EGFR. 
 
Discussion 
Mice homozygous for an Egfr null allele die pre- or peri-natally depending on genetic 
background (Sibilia and Wagner, 1995; Threadgill et al., 1995). This prevents the study of 
EGFR function in postnatal tissues or organs. To overcome this limitation, an Egfr 
conditional allele was generated using the Cre-loxp system, which supports inactivation of 
Egfr in a spatially and/or temporally controlled manner. To inactivate genes in a spatially 
controlled manner, mice with conditional alleles are crossed to mice carrying a Cre transgene 
in which Cre is expressed under control of a tissue-specific promoter. To inactivate a gene of 
interest in a spatially and temporally controlled manner, a combination of an inducible 
system with the cre/loxp system is required.  
Although the Cre/loxp system can be used to knockout a gene of interest in a tissue-
specific pattern, mosaicism commonly occurs. Many Cre transgenic lines are not 100% 
efficient causing partial deletion of the conditional allele. This can complicate interpretation 
of the results if a small population of wildtype cells can prevent abnormal phenotypes, like 
when the target gene acts in noncell-autonomous manner (Kwan, 2002; Nagy, 2000).  
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Three targeting vectors were built to generate an Egfr conditional allele. However, 
vectors 1 and 2 had very low targeting frequencies. There are several factors that can affect 
targeting frequency, including position effect and the amount of homology. To improve the 
targeting frequency, the homologous region in vector 3 was greatly increased and the size of 
the selection cassette reduced. This was achieved by replacing a tk-neo cassette (3.5 kb) in 
vectors 1 and 2 with a neo cassette (2.1 kb) in vector 3. As the results shown (Table 2-1), the 
targeting efficiency was greatly improved in vector 3. In order to increase the size of the 
homologous region in vector 3, a different design was used. The design of vectors 1 and 2 
was to inactivate Egfr by deletion of exons 2-4, while in vector 3, the design was to 
inactivate Egfr by deleting only exon 3. Deletion of exon 3 introduces a frameshift resulting 
in two stop codons in exon 4 and early termination of translation. In addition, exon 3 encodes 
residues 57-117, which is part of the L1 subdomain of the extracellular domain that is 
essential for lignd-binding (Garrett et al., 2002; Reiter et al., 2001).  Thus, removal of exon 3 
should ensure an inactive Egfr allele upon Cre-mediated recombination.  
For gene targeting, the neo selectable marker provides resistance to G418 allowing 
the identification of ES cell colonies that have been potentially targeted by positive selection. 
However, the presence of the neo cassette within an intron may interfere with expression of 
the targeted allele by reducing gene expression or causing aberrant splicing, thus creating a 
hypomorphic allele. This result may be due to the fact that the neo cassette contains cryptic 
splice sites (Meyers et al., 1998; Nagy et al., 1998). To avoid the possibility of interference 
of gene expression, transient expression of Cre in targeted ES cells was performed by 
electroporation to remove the neo cassette that is flanked by two loxp insertions. However, a 
third loxp insertion exists within another intron of Egfr to permit gene inactivation that may 
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also interfere with splicing. Therefore, an RT-PCR analysis was performed to show that no 
alternative splicing occurs in the targeted Egfr locus. 
The success of the knockout technology relies on the pluripotency of ES cells, which 
allows ES cells to contribute to all cell lineages, including the germ line of resulting 
chimeras. Of four chimeras from CD1 embryos, one was sterile. It is likely to be an XX ↔ 
XY chimera, which was morphologically male but was sterile due to the presence of female 
germ cells in the gonads (Koopman et al., 1991). The remaining fertile chimeras each 
produced ten litters, but none transmitted the agouti coat color predicted from the ES cell 
contribution. These chimeras had very low coat color chimerism (5-25%), suggesting that 
CD1 embryos are not suitable hosts for microinjection of 129-derived ES cells. Previous 
studies with CD1 and MF1 embryo-derived chimeras reached similar conclusions, consistent 
with our result. It was concluded that the genetic background has a profound influence on the 
degree of ES cell colonization to different tissues (Schwartzberg et al., 1989). Most likely 
CD1 embryos are predominant over the injected 129 ES cells in contributing to the germ line, 
possibly due to the faster growth of CD1 embryos. Ten high coat color contribution chimeras 
were obtained when using C57BL/6 host blastocysts. Since the coat color chimerism is 
positively correlated with germ line transmission (Forsthoefel et al., 1983; Mystkowska et al., 
1979), five chimeras with over 85% coat color chimerism were chosen to cross with 
C57BL/6 and 129 SvEv females. As expected, agouti progeny were obtained from the 
crosses that carried the Egfrtm1Dwt conditional allele.      
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Fig. 2-1 Cre/loxp system. (A) Loxp contains two 13-bp inverted repeats and 
an 8-bp core sequence which defines the orientation of loxp site. (B) The 
Cre-mediated loxp recombinations can result in deletions/integrations or 
inversions when two loxp sites are aligned in cis, and translocations when 
two loxp sites are aligned in trans. Figure modified from (Kwan, 2002). 
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Fig. 2-2 Strategy for generating chimeras. (A) Creation of targeting vector. (B) 
Identification of targeted ES cell clones. (C) Removal of the neo cassette. (D) 
Injection of targeted ES cells into host blastocysts. (E) Transfer of blastocysts 
into uteri of surrogate dams. (F) Birth of chimeras. (E) Identification of progeny 
from chimeras carrying the engineered allele. Figure modified from (Yu and 
Bradley, 2001). 
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Fig. 2-3 Constructs for generating an Egfr conditional allele. The targeting 
efficiency was increased as the amount of homologous regions was increased 
and the amount of mismatch region was decreased. 
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Fig. 2-4 Targeting efficiency of vector 3. (A) Neo resistant colonies analyzed by 
Southern blot for proper targeting (check-marked lanes have targeted clones). (B) 
One in 13 targeted clones lost the intronic loxp site (No. 12). (C) Verification of 
the remaining 12 targeted clones confirmed by Southern blot analysis with EcoN1 
and Nde1 digestions. Note that No. 6 may have an extra insertion. 
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Fig. 2-5 Removal of the neo cassette by partial Cre-mediated loxp 
recombination. (A) Structure of floxed and wildtype alleles. The arrows 
indicate locations of the forward and reverse primers for PCR. (B) PCR 
results indicating the clones in which partial loxp recombination was correct 
(check-marks). 
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Fig. 2-6 Structure of wildtype and engineered Egfr alleles. The Egfrtm1Dwt allele 
was generated by removing the neo cassette from the vector 3 allele in ES cells, 
while the Egfr∆ allele can be created by deleting loxp-flanked exon 3 from the 
Egfrtm1Dwt allele. 
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Fig. 2-7 Splicing from the Egfrtm1Dwt allele. (A) The structure of the 
Egfrtm1Dwt allele. Arrows indicate the location of forward and reverse 
primers in exons 2 and 4 for RT-PCR. (B) RT-PCR results from targeted 
ES clones was identical to that from wildtype clones. 
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Fig. 2-8 Generation of chimeras. (A-D) Four chimeras with low coat color 
chimerism (estimated 5-30%) were generated using CD1 blastocysts as host 
embryos.  
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CHAPTER 3 
CHARACTERIZATION OF Egfrtm1Dwt AND Egfr∆ ALLELES 
 
Abstract 
After the Egfr conditional knockout mouse model was generated, the Egfrtm1Dwt and 
Egfr∆ alleles were characterized. To determine whether the Egfrtm1Dwt allele has wildtype 
activity, Egfrtm1Dwt/+ mice were crossed with Egfrtm1Mag/+ mice carrying a null allele to 
generate Egfrtm1Dwt/tm1Mag offspring as well as control littermates. All mice from this cross 
were viable, fertile and normal in appearance, indicating that the Egfrtm1Dwt allele possesses 
wildtype activity. To prove that Egfr∆ allele functions as a null allele, Egfr∆/∆, EIIa-Cre mice 
were generated, which all died at mid-gestation and displayed moderate to severe placental 
defects with a reduced spongiotrophoblast layer and a disorganized architecture of the 
labyrinth layer that was identical to the phenotype reported for Egfr null mice. Thus, the 
Egfr∆ allele functions as a null allele. In addition, to test if the Egfrtm1Dwt allele can be 
inactivated tissue-specifically, Egfrtm1Dwt/tm1Dwt, K14-Cre mice were produced. As expected, 
these mice were viable but exhibited wavy coat phenotype, highly similar to Egfrwa2/wa2 mice, 
homozygous for a hypomorphic allele of Egfr. Overall, these results reveal that this new 
mouse model can be used to inactivate Egfr conditionally for functional analysis of EGFR in 
adult tissues. 
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Introduction 
Egfr has been extensively studied to investigate its physiological role in many organs 
and tissues using mouse models with different Egfr alleles, including targeted, spontaneous, 
N-ethyl-N-nitrosourea (ENU)-mutated and transgenic alleles. Three targeted null mouse 
models (Egfrtm1Mag, Egfrtm1Wag and Egfrtm1Rdk) have been created, and depending on genetic 
background, die of placental defect at mid-gestation or perinatal stages. The placental defect 
includes a greatly reduced spongiotrophoblast layer and a disorganization of the labyrinth 
layer indicating that EGFR signaling is required for normal placental development. 
Phenotypes observed in Egfr null mice surviving to term include abnormalities of the skin 
and gastrointestinal tract, immature lungs, and cell death in the cortex and olfactory bulb 
(Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995). Egfr null mice 
also have abnormal craniofacial development including defects in palate closure, elongated 
snouts, and underdeveloped lower jaws (Miettinen et al., 1999). 
Another allele that has been frequently utilized for analysis of EGFR function is the 
Egfrwa2 allele that has a spontaneously arising point mutation causing a Val743Gly 
substitution in the ATP-binding site of the tyrosine kinase domain. The receptor produced 
from the Egfrwa2 allele has an 80-95% reduction in EGFR activity. Studies using Egfrwa2 
homozygous mice have shown an important role for EGFR signaling during anagen phase of 
the hair cycle (Mak and Chan, 2003); EGFR is normally localized to the outer root sheath of 
hair follicles (Luetteke et al., 1994). Egfrwa2 homozygous dams display smaller mammary 
glands with lower milk production that causes increased mortality of their neonates (Fowler 
et al., 1995). Egfrwa2 homozygous mice also exhibit enlarged aortic valves that are enhanced 
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by heterozygosity for a targeted mutantion in Ptpn11, which encodes the protein-tyrosine-
phosphatase SHP2 (Chen et al., 2000).  
There are two ENU-induced Egfr mutant alleles that have been reported, EgfrWa5 and 
EgfrDsk5. The EgfrWa5 allele is an antimorphic allele, also called a dominant-negative, 
containing a point mutation leading to an Asp833Gly substitution in a highly conserved DFG 
motif within the kinase domain. Mice heterozygous for the EgfrWa5 allele have open eyes and 
wavy coats similar to Egfrwa2/wa2 mice, while EgfrWa5 homozygous embryos die at mid-
gestation owing to placental defects that are similar to those of Egfr null embryos. In 
addition, the EgfrWa5 allele enhances the Egfrwa2 hypomorphic phenotype in compound 
heterozygotes (Du et al., 2004; Lee et al., 2004). The other ENU-induced allele is the 
hypermorphic EgfrDsk5 allele that contains a missense mutation resulting in a Leu863Gln 
substitution lying within the tyrosine kinase domain; receptors produced by EgfrDsk5 have 
increased kinase activity. Mice heterozygous or homozygous for EgfrDsk5 display pigment 
accumulation and melanocytosis progressively with age, which is secondary to 
hyperkeratosis and epidermal thickening (Fitch et al., 2003).  
A humanized allele, EgfrKI has also been created, containing a human EGFR cDNA 
that replaces the mouse Egfr allele. Mice homozygous for EgfrKI can live up to six months, 
but display growth retardation, hair follicle defects, increase in differentiated chondrocytes 
and osteoblasts in bone and heart hypertrophy with abnormal semilunar valves (Sibilia et al., 
2003). Taken altogether, mice carrying different Egfr alleles have been proven to be 
important tools for analyzing EGFR functions in vivo, and have revealed a diversity of EGFR 
functions across multiple tissues. After generating an Egfr conditional knockout mouse
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model, its activity was functionally characterized to show that the Egfrtm1Dwt allele will be a 
useful tool for more detailed analyses of EGFR functions, especially in the adult mice.  
   
Materials and methods 
Mice and crosses 
Egfr mutant mice used in these experiments include Egfrtm1Dwt/+ (129 background), 
Egfrtm1Dwt/tm1Dwt (129,B6 mixed background) and Egfrtm1Mag/+ (129 background) (chapter 2; 
Threadgill et al., 1995). EIIa-Cre (B6,FVB mixed background) transgenic mice were a gift 
from Dr. Mark Majesky (UNC), and K14-Cre (FVB background) transgenic mice were 
obtained from The Jackson Laboratory.  
 The activity of the Egfrtm1Dwt allele was evaluated by crossing Egfrtm1Dwt/+ mice with 
Egfrtm1Mag/+ mice. Egfrtm1Dwt/tm1Mag and Egfrtm1Mag/+ F1 mice were used as experimental and 
control groups, respectively. Body weights were measured and compared by gender. 
 To verify if Egfr∆ allele is a null allele, Egfrtm1Dwt/tm1Dwt mice were crossed to EIIa-
Cre mice to generate Egfr∆/+, EIIa-Cre progeny. Egfr∆/+, EIIa-Cre mice were then crossed 
with Egfrtm1Dwt/tm1Dwt mice to generate Egfr∆/+, EIIa-Cre and Egfr∆/∆, EIIa-Cre mice. The 
placentas at E12.5 were histologically examined. 
To identify whether the Egfrtm1Dwt allele functions as a tissue-specific conditional 
allele, Egfrtm1Dwt/tm1Dwt mice were crossed to K14-Cre mice to obtain Egfrtm1Dwt/+, K14-Cre 
progeny, which were crossed to Egfrtm1Dwt/tm1Dwt mice to generate Egfrtm1Dwt/tm1Dwt, K14-Cre 
and Egfrtm1Dwt/+, K14-Cre offspring that were used as experimental and control groups, 
respectively. The coat phenotypes were examined by visual inspection. 
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Histological examination 
Placentas from E12.5 embryos were isolated and fixed in 10% neutral buffered formalin 
solution (NBF) for 24 hours. After fixation, the samples were dehydrated using a graded 
alcohol series, 70% (1 hr), 85% (1 hr), 95% (1 hr), 100% (1 hr) and 100% (1 hr) alcohol 
followed by xylene twice (1 hr for each). Finally, the samples were infiltrated with paraffin at 
60 °C twice (1 hr for each) before embedding and sectioning (7 µm). Sections were stained 
with hematoxylin and eosin and after mounting, examined under light microscopy. 
PCR genotyping 
Tail DNA samples were examined for the Egfrtm1Dwt allele by amplifying for 35 cycles (30 s 
at 94°C, 1 min at 60°C and 1 min at 72°C) using Taq DNA polymerase (Qiagen) and a 
GeneAmp PCR system 9700 (Applied Biosystems). The primers were lox3s 5’-
CTTTGGAGAACCTGCAGATC-3’ and lox3as 5’-CTGCTACTGGCTCAAGTTTC-3’. A 
375 bp PCR product was detected from the Egfrtm1Dwt allele and a 320 bp PCR product from 
the wildtype allele. For Egfr∆ allele, genomic DNA from embryos at E10.5 or E12.5 was 
amplified for 40 cycles (30 s at 94°C, 20 s at 60°C and 20 s at 72°C). The primers were 
Delta-3 5’-CTCAGCCAGATGATGTTGAC-3’ and Delta-4 5’-
CCTCGTCTGTGGAAGAACTA-3’.  A 129 bp PCR fragment was amplified from the Egfr∆ 
allele. The Egfr null allele, Egfrtm1Mag, was detected by amplifying DNA for 40 cycles (30 s 
at 94°C, 30 s at 55°C and 1 min at 72°C). The primers were EGFR common 5’-
GCCCTGCCTTTCCCACCATA-3’ and EGFR knockout 5’-
AACGTCGTGACTGGGAAAAC-3’. A 450 bp PCR product was detected from the Egfr 
null allele. 
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For EIIa- and K14-Cre transgenes, genomic DNA was amplified for 38 cycles (30 s 
at 94°C, 1 min at 56°C and 1 min at 72°C). The primers were CRE-1 5’-
GTGATGAGGTTCGCAAGAAC-3’ and CRE-2 5’-AGCATTGCTGTCACTTGGTC-3’. A 
278 bp PCR fragment was amplified from the Cre transgenes. 
Western blot analysis  
E10.5 embryos and yolk sac with Egfr+/∆, EIIa-Cre and EgfrΔ/Δ, EIIa-Cre genotypes were 
homogenized with tissue lysis buffer at a ratio of 10 ml tissue lysis buffer/g of tissue. The 
tissue lysis buffer contained 20 mM HEPES, pH 7.4, 150 mM MaCl; 2 mM EDTA, pH 8.0, 2 
mM ethylenebis(oxyethylenenitrilo) tetraacetic acid (EGTA), pH 8.0, 1% Triton X-100, and 
10% glycerol adjusted to final pH 7.4 before adding protease inhibitors (1 mM phenyl 
sulfonyl fluoride [PMSF] in isopropanol, 10 µg/ml leupeptin and 10 µg/ml aprotinin) and 
phosphatase inhibitors (1 mM sodium orthovanadate [Na3VO4] and 1 mM NaF).  
Twenty five micrograms of total protein from each sample in homogenized lysate was 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and 
then transferred to PVDF membrane. The membrane was placed in a blocking solution 
containing 5% milk in TBST (150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.1% Tween-20), 
and probed with a primary antibody, sheep anti-EGFR polyclonal IgG (Upstate) in blocking 
solution (1:500) overnight. The membrane was then washed with TBST four times (15 min 
each), and incubated in blocking solution with second antibody, rabbit anti-sheep polyclonal 
IgG conjugated with horseradish peroxidase (HRP) (1:10000) for 1 hour. The membrane was 
washed with TBST four times again, incubated with enhanced chemiluminescent (ECL) 
substrate (Pierce) for 1-5 minutes and subjected to X-ray film photography. The amount of ß-
tubulin in each sample was used as an internal control. The primary antibody for ß-tubulin 
 52 
was mouse anti- ß-tubulin polyclonal IgG (1:1000), and the second antibody was goat anti-
mouse polyclonal IgG with HRP conjugated (1:15000). 
Statistical analysis 
An unpaired t-test was used for all comparisons. The data was expressed as mean ± SEM. 
 
Results 
Egfrtm1Dwt allele possesses wildtype function 
 To evaluate the activity of the Egfrtm1Dwt allele, Egfrtm1Dwt/+ mice were crossed to 
Egfrtm1Mag/+ mice. Progeny with Egfrtm1Dwt/tm1Mag and Egfrtm1Mag/+ genotypes were observed 
for abnormal phenotypes and their body weights were measured at two months of age. 
Egfrtm1Dwt/tm1Mag mice developed normally with a wildtype appearance, including their coat 
appearance, and also had wildtype fertility (Fig. 3-1). The average body weights of 
Egfrtm1Dwt/tm1Mag males (n=7) and females (n=5) were 22.07 ± 0.60 and 17.54 ± 0.92 g, 
respectively, while the average body weights of control Egfrtm1Mag/+ males (n=6) and females 
(n=6) were 22.63 ± 1.02 and 17.78 ± 0.85 g, respectively. Statistically, there was no 
significant difference between genotypes (p = 0.63 and 0.85 for males and females) (Fig. 3-
2). This result shows that the Egfrtm1Dwt allele produces an EGFR with wildtype function. 
 
Egfr∆ allele is a null allele 
 The Egfr∆ allele, predicted to act like a null allele, is produced after Cre-mediated 
recombination. To test this prediction, the Egfr∆ allele was produced by crossing 
Egfrtm1Dwt/tm1Dwt mice with EIIa-Cre transgenic mice. The adenovirus EIIa promoter 
expresses Cre during preimplantation development, as early as the one-cell embryo stage 
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(Lakso et al., 1996). After intercrossing the progeny, placentas from Egfr∆/∆, EIIa-Cre 
embryos were grossly smaller in size than those of wildtype littermates. Histological analysis 
showed that the spongiotrophoblast and labyrinth layers were affected. In the 
spongiotrophoblast layer, the numbers of spongiotrophoblast and glycogen cells were 
moderately to severely decreased, with few spongiotrophoblast cells remaining in some 
Egfr∆/∆, EIIa-Cre placentas. The labyrinth layer in the mutant placentas had a disorganized 
architecture, which was also reduced in size (Fig. 3-3). Amorphous materials were 
commonly observed in the Egfr mutant placentas with aggregates of multiple nuclei, which 
have been reported in placentas from other gene knockouts (Parekh et al., 2004; Ware et al., 
1995). Western blot analysis for EGFR revealed total loss of EGFR in placentas from Egfr∆/∆, 
EIIa-Cre embryos at E10.5 (Fig.3-4). Taken together, these results are consistent with Egfr∆ 
being a null allele (Sibilia and Wagner, 1995; Threadgill et al., 1995). 
 
The Egfrtm1Dwt allele can be inactivated tissue-specifically 
 To test whether the Egfrtm1Dwt allele can be inactivated tissue-specifically, 
Egfrtm1Dwt/tm1Dwt mice were crossed to K14-Cre mice that express high levels of Cre 
recombinase activity in the developing skin at E14.5 (Dassule et al., 2000). Egfrtm1Dwt/tm1Dwt, 
K14-Cre mice were obtained and were viable and fertile. However, unlike their wildtype 
littermates that had normal, straight coat hairs, Egfrtm1Dwt/tm1Dwt, K14-Cre mice displayed 
wavy hair (Fig. 3-5), remarkably similar to the phenotype of Egfrwa2/wa2 mice (Keeler; 1935; 
Luetteke et al., 1994; Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 
1995). This result indicates that the Egfrtm1Dwt allele can be inactivated in a tissue specific 
pattern.  
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Discussion 
Insertions of loxp sites have been considered to interfere with gene expression. 
Consequently, the Egfrtm1Dwt allele was extensively characterized and shown to possess 
wildtype function. Although in vitro analysis using RT-PCR revealed that no alternative 
RNA splicing was detectable in targeted ES cells (Chapter 2, Fig. 2-7), further in vivo 
confirmation was performed. Egfrtm1Dwt/tm1Mag mice developed normally and were fertile 
indicating that the Egfrtm1Dwt allele produces sufficient EGFR to function normally.  
Inactivation of the Egfrtm1Dwt allele by Cre recombinase at an early embryonic stage 
was used to generate Egfr∆/∆, EIIa-Cre embryos, which displayed the same defective 
placental phenotype as reported previously for constitutional Egfr null alleles (Sibilia and 
Wagner, 1995; Threadgill et al., 1995). Placentas from Egfr∆/∆, EIIa-Cre embryos had a 
greatly reduced spongiotrophoblast layer and an abnormal labyrinth architecture. The proper 
function of the Egfrtm1Dwt allele was validated through tissue-specific generation of Egfr∆/∆ in 
skin using K14-Cre. Overall, these results provide evidence to show that the Egfr conditional 
allele can be inactivated in a spatially and temporally controlled manner.  
Although the results conclusively showed proper function for the Egfrtm1Dwt allele, 
mutant mice from the same litter frequently had different levels of phenotypic severity. It is 
unclear whether this mosaicism is due to variable expression levels of Cre recombinase in 
individual mice, different accessibility of Cre recombinase to the conditional allele or for 
another unknown reason. Nonetheless, awareness potential mosaicism is important, 
especially when the conditional alleles code for proteins that act in a non-cell-autonomous 
manner such that a small fraction of wildtype cells may completely rescue a mutant 
phenotype (Kwan, 2002). However, for subtle phenotypes, a sufficient and constantly 
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expressed Cre transgene could be crucial for experimental success. Fortunately, for 
Egfrtm1Dwt, the phenotypes were evident. 
Despite the uncertainty, conditional knockout mouse models provide significant 
benefits. The major benefit is that genes can be inactivated spatially and temporally, 
overcoming the limitations caused by embryonic lethality of some constitutional knockout 
alleles. Since conditional alleles have been generated for all four Erbb genes (Crone et al., 
2002; Long et al., 2003; Qu et al., 2006), it is now possible to create double mutations to 
enhance understanding of ERBB interaction.  
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Fig. 3-1 Normal activity of the Egfrtm1Dwt allele. (A) Egfrtm1Mag/+ mouse. (B) 
Egfrtm1Dwt/tm1Mag mouse. (C) Genotypes of eleven mice. No. 1, 3, 7, and 11 
are Egfrtm1Dwt/tm1Mag mice. 
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Fig. 3-2 Comparison of body weight between Egfrtm1Dwt/tm1Mag and 
Egfrtm1Mag/+ mice (p=0.85 for females and 0.63 for males). 
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Fig. 3-3 Placental defect in Egfr∆/∆, EIIa-Cre mice. (A) Wildtype placenta 
(30X, H&E stain). (B) Egfr∆/∆, EIIa-Cre placenta, which is thinner and 
smaller than wildtype (30X, H&E stain). (C) Wildtype placenta at higher 
magnification (100X, H&E stain). (D) Egfr∆/∆, EIIa-Cre placenta with 
reduced spogiotrophoblast layer and disorganized labyrinth layer. 
Amorphous material, indicated by white arrow, is common in mutant 
placentas (100X, H&E stain). DC, decidua; ST, spongiotrophoblast layer; 
LT, labyrinth layer. 
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Fig. 3-4 Western blot analysis displaying loss of EGFR of 
protein in Egfr∆/∆, EIIa-Cre embryos at E10.5. 
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Fig. 3-5 Tissue-specific deletion of Egfr. (A) Egfrtm1Dwt/+, K14-cre mouse (3 
months old). (B) Egfrtm1Dwt/tm1Dwt, K14-cre mouse (3 months old) displaying a 
wavy coat. 
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CHAPTER 4 
CHARACTERIZATION OF EGFR FUNCTION WITHIN THE 
BRAIN 
 
Abstract 
 In order to analyze EGFR function within the brain and to investigate the underlying 
mechanism responsible for neurodegeneration of Egfr null mice, three Cre transgenic lines 
expressed in the embryonic epiblast (Sox2-Cre) or neuroprogenitor cells (Nestin-Cre and 
hGFAP-Cre) were crossed with mice carrying the Egfrtm1Dwt conditional allele to generate 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre (as well as Nestin-Cre or hGFAP-Cre) mice. Egfrtm1Dwt/tm1Dwt mice 
also carrying Sox2-Cre or Nestin-Cre displayed growth retardation and neurodegeneration in 
the cortex, olfactory bulb and areas surrounding lateral ventricle including corpus callosum, 
the fimbria of the hippocampus and subventricular zone (SVZ) and rostral extension (RE). 
These results were consistent with the phenotype of Egfr null mice. Conversely, 
Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice showed no damage within the brain. At E18.5 there were 
no differences between body weights of Egfrtm1Dwt/tm1Dwt mice also carrying Sox2-Cre, 
Nestin-Cre or hGFAP-Cre, although Egfrtm1Dwt/tm1Dwt, Sox2-Cre (or Nestin-Cre) showed 
postnatal growth defects. TUNEL analysis revealed that the neurodegeneration was caused 
by induction of apoptosis. Nestin-Cre and hGFAP-Cre mice were crossed with the ROSA26-
lacZ reporter mice (R26R) to locate differences in the distribution of Cre expression in the 
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brain. Results indicated that the hGFAP-Cre line expresses Cre in the progenitors of the 
cortex, olfactory bulb, SVZ, RE and rostral migratory stream (RMS) but unlike Nestin-Cre 
not the choroid plexus, despite the lack of neurodegeneration in Egfrtm1Dwt/tm1Dwt, hGFAP-Cre 
mice. These results suggest that neuronal or astrocytic death in the absence of EGFR 
signaling is a secondary effect, possibly mediated by the choroid plexus. 
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Introduction 
 EGFR is widely expressed in the central nervous system (CNS). Egfr transcripts are 
primarily restricted to the hindbrain at E13 but more broadly in the ventricular zone (VZ) and 
SVZ of forebrain at E17. Egfr is also expressed in the cortex, striatum, hippocampus and 
cerebellum of the developing and adult mouse brains (Fox and Kornblum, 2005). Compared 
with primary rat neuron culture, Egfr is highly expressed in astrocytes and oligodendrocytes 
(Mazzoni and Kenigsberg, 1994; Wang et al., 1989), implying the importance of EGFR 
signaling in development, function or survival of astrocytes and oligodendrocytes.  
During postnatal development of the rat optic nerve, activation of EGFR directs 
astrocytes to form cribriform structures that group axons into bundles (Liu and Neufeld, 
2004a, b). EGFR signaling is also required for the proliferation of both retinal progenitors 
and Muller glial cells, but Egfr expression declines when the retina matures (Close et al., 
2006). Along with TGFA stimulation, overexpression of EGFR promotes retinal progenitor 
cells to differentiate into Muller glial cells rather than rod photoreceptors (Lillien, 1995), 
indicating that a balance in EGFR signal is essential for normal retinal development. Other 
studies have shown that after unilateral lysolecithin (LPC)-induced demyelination of the 
mouse corpus callosum, overexpression of EGFR enhances oligodendrocyte progenitor 
proliferation, increasing the number of oligodendrocytes distributed throughout the lesion, 
promoting axonal remyelination (Aguirre et al., 2007). Studies have also confirmed that 
neural stem cells from the developing or adult mouse germinal zones increase proliferation in 
response to EGFR activation (Ciccolini, 2001; Gritti et al., 1999; Reynolds et al., 1992; 
Tropepe et al., 1999). Additionally, the timing and level of EGFR expression in neural stem 
cells influence their migration properties and cell fate choices during cortical development 
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(Burrows et al., 1997). EGFR has been further demonstrated to promote cell migration in 
neural stem cells or other cell types in the developing telencephalon, possibly through HB-
EGF, or other ligands serving as chemoattractant (Caric et al., 2001). 
EGFR signaling appears to have opposing functions on neurite outgrowth. In some 
reports, EGFR signaling enhances neurite outgrowth induced by suppressor of cytokine 
signaling-2 (SOCS2) in the cortical neurons (Goldshmit et al., 2004); EGFR mediates the 
enhancement of neurite outgrowth and synaptic transmission by versican G3 domain in the 
embryonic hippocampal neurons (Xiang et al., 2006). Conversely, in other cases EGFR 
signaling displays inhibitory effect on neurite outgrowth. Calcium-dependent activation of 
EGFR mediates the inhibition of neurite outgrowth by myelin-associated inhibitors and 
chondroitin sulfate proteoglycans (CSPGs) (Koprivica et al., 2005); EGFR can be 
transactivated by binding fibrinogen to β3 integrin to mediate the inhibition of neurite 
outgrowth (Schachtrup et al., 2007). 
Egfr null mice develop neurodegeneration exclusively in the cortex and olfactory 
bulb (Sibilia et al., 1998; Threadgill et al., 1995). In order to further understand how the loss 
of EGFR leads to neurodegeneration, an Egfr conditional allele (Egfrtm1Dwt) was used to 
remove EGFR specifically in the brain. 
 
Materials and methods 
Mice and crosses 
The conditional Egfrtm1Dwt on a 129,B6 mixed background was previously described (Chapter 
2).  Sox2-Cre (B6,CBA mixed backgound), Nestin-Cre (B6,CBA mixed background), and 
 67 
hGFAP-Cre (FVB/N background) mice were obtained from The Jackson Laboratory. The 
Rosa26 reporter (R26R) was a gift from Dr. Terry Van Dyke (University of North Carolina). 
To analyze the requirement for EGFR in the brain, Egfrtm1Dwt/tm1Dwt mice were crossed 
with Sox2-Cre, Nestin-Cre or hGFAP-Cre mice to generate Egfrtm1Dwt/+, Sox2-Cre (Nestin-
Cre and hGFAP-Cre) F1 mice, which were then backcrossed to Egfrtm1Dwt/tm1Dwt mice to 
generate Egfrtm1Dwt/tm1Dwt, Sox2-Cre (Nestin-Cre and hGFAP-Cre) and control littermates. In 
general, Egfrtm1Dwt/tm1Dwt, Sox2-Cre (Nestin-Cre and hGFAP-Cre) experimental mice were 
compared with Egfrtm1Dwt/+, Sox2-Cre (Nestin-Cre and hGFAP-Cre) control mice. 
To locate differences in Cre expression between Nestin-Cre and hGFAP-Cre, crosses 
were performed with R26R reporter mice to generate R26R, Nestin-Cre and R26R, hGFAP-
Cre mice. 
PCR genotyping 
The Egfrtm1Dwt allele was amplified from genomic DNA for 35 cycles (30 s at 94°C, 1 min at 
60°C and 1 min at 72°C) using Taq DNA polymerase (Qiagen) and a GeneAmp PCR system 
9700 (Applied Biosystems). The primers were lox3s 5’-CTTTGGAGAACCTGCAGATC-3’ 
and lox3as 5’-CTGCTACTGGCTCAAGTTTC-3’. A 375 bp PCR product was detected from 
the Egfrtm1Dwt allele and a 320 bp PCR product from the wildtype allele. For the Egfr∆ allele, 
genomic DNA was amplified for 40 cycles (30 s at 94°C, 20 s at 60°C and 20 s at 72°C). The 
primers were Delta-3 5’-CTCAGCCAGATGATGTTGAC-3’ and Delta-4 5’-
CCTCGTCTGTGGAAGAACTA-3’.  A 129 bp PCR fragment was detected from the Egfr∆ 
allele. 
For the Sox2-Cre and Nestin-Cre transgenes, genomic DNA was amplified for 38 
cycles (30 s at 94°C, 1 min at 56°C and 1 min at 72°C). The primers were cre-1 5’-
 68 
GTGATGAGGTTCGCAAGAAC-3’ and CRE-2 5’-AGCATTGCTGTCACTTGGTC-3’. A 
278 bp PCR fragment was amplified that corresponded to the Cre transgenes. For the 
hGFAP-Cre transgene, genomic DNA was amplified for 38 cycles (30 s at 94°C, 1 min at 
51°C and 1 min at 72°C). The primers were MR1900 5’-ACTCCTTCATAAAGCCCT-3’ 
and MR1901 5’-ATCACTCGTTGCATCGACC-3’. A 190 bp PCR fragment was amplified 
from the hGFAP-Cre transgene. For the R26R transgene, genomic DNA was amplified for 38 
cycles (30 s at 94°C, 1 min at 60°C and 1 min at 72°C). The primers were Rosascom 5’-
AAAGTCGCTCTGAGTTGTTAT-3’ and Rosasneo 5’-GCGAAGAGTTTGTCCTCAACC-
3’. A 300 bp PCR fragment was amplified from the R26R transgene. 
Measurement of blood glucose 
Mice at 24 days of age were fasted for 24 hours before taking blood glucose measurements. 
Blood glucose was measured from the tail using a Freestyle blood glucose monitoring system 
(TheraSense) and Freestyle flash test strips.  
Histology 
Mice were anesthetized by isoflurane (Abbott) and perfused with 4% paraformaldehyde. 
Mouse brains were collected and fixed in 4% paraformaldehyde for 24 hours before 
dehydrating through a 70% (1 hr), 85% (1 hr), 95% (1 hr) and 100% (2 x 1 hr) alcohol series. 
Samples were washed twice in xylene (1 hr for each), and then infiltrated in paraffin at 60 °C 
twice (1 hr each). Finally, the samples were embedded in paraffin and sectioned (7 µm) with 
a microtome (Leica). Sections were stained with hematoxylin and eosin and after mounting, 
examined by light microscopy. 
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TUNEL assay 
TUNEL was performed using the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit 
(Chemicon) according the protocol provided by the manufacturer. The process included (1) 
deparaffinization of tissue sections with xylene, (2) pretreatment of tissues with proteinase K 
(20 µg/ml), (3) quenching of endogenous peroxidase with 3% hydrogen peroxide, (4) 
application of equilibration buffer, (5) application of working strength TdT enzyme, (6) 
application of stop/wash buffer, (7) application of anti-digoxigenin conjugate, (8) washing in 
PBS, (9) development of color in peroxidase substrate, (10) washing specimens, and (11) 
counterstaining the specimens with 0.5% methyl green.  
Cryosectioning 
R26R, Nestin-Cre and R26R, hGFAP-Cre mice at 6 weeks of age were anesthetized by 
isoflurane (Abbott) and perfused with cold PBS. Mouse brains were collected and fixed in 
2% paraformaldehyde for 30 min. Brain samples were then infiltrated with 30% sucrose 
phosphate buffer at 4°C overnight before placing in the cryomolds, embedding with tissue 
freezing medium (OCT) and immersing in cold isopentane. The sample blocks were 
sectioned (10 µm) with a cryostat (Leica). 
X-gal staining 
Cryosections of brain samples were fixed with 2% paraformaldehyde on ice for 10 min, and 
washed in rinse buffer (2 mM MgCl2, 1X PBS, pH 7.2) followed by detergent rinse buffer (2 
mM MgCl2, 0.02% Igepal CA630, 0.01% sodium deoxycholate, 1X PBS, pH 7.2) for 10 min 
each. X-gal staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 
0.1% X-gal [5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside; Denville Scientific], 2 mM 
MgCl2, 0.02% Igepal CA630, 0.01% sodium deoxycholate) was applied to the brain 
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cryosections and incubated at 37°C for 4-5 hours in a dark, humidified box. Cryosections 
were counterstained with 0.1X hematoxylin and 1X eosin Y.  
Western blot analysis 
Brains were collected from mice at 8 days of age, cut into two parts (the prosencephalon and 
the combined mesencephalon and rhombencephalon) and homogenized with tissue lysis 
buffer using a ratio of 10 ml tissue lysis buffer/g of tissue. The tissue lysis buffer contained 
20 mM HEPES, pH 7.4, 150 mM MaCl; 2 mM EDTA, pH 8.0, 2 mM EGTA, pH 8.0, 1% 
Triton X-100, and 10% glycerol, adjusted to final pH 7.4; also added with protease inhibitors 
(1 mM phenyl sulfonyl fluoride [PMSF] in isopropanol, 10 µg/ml leupeptin and 10 µg/ml 
aprotinin) and phosphatase inhibitors (1 mM sodium orthovanadate [Na3VO4] and 1 mM 
NaF).  
Forty micrograms of total protein from each sample were separated using SDS-
PAGE, and then transferred to PVDF membrane. Subsequently, the membrane was blocked 
in 5% milk in TBST (150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.1% Tween-20), and probed 
with primary antibody, sheep anti-EGFR polyclonal IgG (Upstate), in blocking solution 
(1:500) over night. The membrane was then washed with TBST four times (each time for 15 
min), incubated with secondary antibody, rabbit anti-sheep polyclonal IgG conjugated with 
horseradish peroxidase (HRP) in blocking solution (1:10000) for 1 hour. The membrane was 
washed with TBST four times, incubated with enhanced chemiluminescent (ECL) substrate 
(Pierce) for 1-5 minutes, and subjected to X-ray film photography. An anti-ß-tubulin 
antibody was used as a loading control. The primary antibody was a mouse anti-ß-tubulin 
polyclonal IgG (1:1000), and the second antibody was a goat anti-mouse polyclonal IgG 
conjugated with HRP (1:15000). 
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Statistical analysis 
The logrank test was used to analyze survival curves. For other experiments, an unpaired 
Student’s t-test was used. The data was expressed as mean ± SEM, *p<0.05, **p<0.01, 
***p<0.001. 
 
Results 
 Three Cre lines, Sox2-Cre, Nestin-Cre and hGFAP-Cre, were used to analyze the 
function of EGFR in the mouse brain. Sox2-Cre is epiblast-specific (Hayashi et al., 2002), 
which should result in Cre-mediated deletion of Egfrtm1Dwt in all cells of the embryo properly, 
but not extraembryonic cells like those contributing to the placenta. Nestin-Cre expresses in 
neural stem cells (Betz et al., 1996; Tronche et al., 1999), which should result in Cre-
mediated deletion of Egfrtm1Dwt in all cells of the adult brain. Similarly, the hGFAP-Cre line 
expresses Cre in neural stem cells before being extinguished and re-expressed in glial cells 
(astrocytes, oligodendrocytes and microglias) (Zhuo et al., 2001). Since it has been shown 
that Sox2-Cre female mice can transmit Cre activity via a maternal effect to their offspring 
irrespective of whether the Cre transgene is inherited (Hayashi et al., 2003), only male 
Egfrtm1Dwt/+, Sox2-Cre mice were used as parents.  
 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) mice display postnatal lethality and growth 
retardation 
 Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice had open eyes at birth, curly whiskers and a wavy 
coat, and were much smaller than their littermates (Fig. 4-1A). The phenotype in the Sox2-
Cre crosses was very similar to the Egfr null mice surviving past birth. Survival curve for 
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Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice was significantly different from those of the three control 
genotypes (logrank test, p<0.0001; Fig. 4-2A). Over 80% of Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice 
died within two weeks after birth (17/21). However, the remaining mice survived although 
they displayed classical Egfr-mediated hair phenotype. The most likely explanation for the 
variable survival of some Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice is mosaicism in Cre recombinase 
expression. 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre mice were smaller in size compared with their littermates 
(Fig. 4-1B); and there was also a significant difference in the survival curves between 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre mice and the three control genotypes (logrank test, p<0.0001; 
Fig. 4-2B). Over 50% of Egfrtm1Dwt/tm1Dwt, Nestin-Cre mice died within one month after birth 
(17/31), with the surviving mice having only mild defects including reduced growth (Fig. 4-
3). Both Egfrtm1Dwt/tm1Dwt, Sox2-Cre and Nestin-cre mice displayed dehydration and severe 
growth retardation or weight loss before death, although the phenotype of Egfrtm1Dwt/tm1Dwt, 
Sox2-Cre mice was more severe than that of Egfrtm1Dwt/tm1Dwt, Nestin-Cre mice. Since Cre is 
more widely expressed from the Sox2 promoter than Nestin, the higher death rate of 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice may have been due to additional abnormalities of the skin 
and immature lungs (Sibilia and Wagner, 1995; Threadgill et al., 1995), which did not occur 
in Egfrtm1Dwt/tm1Dwt, Nestin-Cre mice.  
In contrast to mice from Sox2-Cre or Nestin-Cre crosses, Egfrtm1Dwt/tm1Dwt, hGFAP-
Cre mice did not display elevated levels of postnatal lethality, but did show wavy coats 
indicative of Cre expression in the skin (Fig. 4-1D). There was no significant difference in 
survival curves (Fig. 4-2C), although the average body weight of Egfrtm1Dwt/tm1Dwt, hGFAP-
Cre mice was less than that of their control littermates at 24 days of age (11.05 ± 0.64 vs 
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13.02 ± 0.56 g, p<0.05 in female; 11.50 ± 0.74 vs 14.18 ± 0.71 g, p<0.05 in male; Fig. 4-4A). 
Nonetheless, all groups reached a similar weight by two months of age (21.25 ± 0.58 vs 
20.63 ± 0.64 g, p=0.48 in female; 26.86 ± 0.64 vs 28.37 ± 0.73 g, p=0.14 in male; Fig. 4-4B). 
In order to determine when the growth retardation of Egfrtm1Dwt/tm1Dwt, Sox2-Cre 
(Nestin-Cre and hGFAP-Cre) mice begins, body weights were measured at E18.5 (Fig. 4-5). 
No significant differences in body weight were detected between the genotypic groups, 
indicating that the growth retardation begins after birth. Surviving Egfrtm1Dwt/tm1Dwt, Nestin-
Cre mice also had much lower levels of blood sugar at 24 days after birth (65.5 ± 6.5 vs 
117.5 ± 6.7 mg/dl, p<0.001 in female; 67.9 ± 8.4 vs 115.7 ± 6.8 mg/dl, p<0.001 in male; Fig. 
4-6A), suggesting that neurodegeneration may affect feeding behavior or metabolism. 
Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice also had significantly lower levels of blood sugar 
compared with their littermates (123.4 ± 4.3 vs 137.1 ± 3.8 mg/dl, p<0.05 in female; 122.8 ± 
6.4 vs 140.1 ± 4.1 mg/dl, p<0.05 in male; Fig. 4-6B). 
 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre and Nestin-Cre but not hGFAP-Cre mice display 
neurodegeneration in the cortex, olfactory bulb and areas surrounding the lateral 
ventricle 
 Histology of the brains from Egfrtm1Dwt/tm1Dwt, Sox2-Cre, (and Nestin-Cre and hGFAP-
Cre) mice was compared to their control littermates. Grossly, the brains of Egfrtm1Dwt/tm1Dwt, 
Sox2-cre (and Nestin-Cre) mice were smaller than those of their littermates. It was common 
to see bleeding in the cortex and olfactory bulb of Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-
Cre) mice. Histological analysis showed that significant cell death in the frontal areas of the 
cortex, caused the cortex to shrink or cavity formation (Fig. 4-7B and D). Apoptotic bodies 
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were found in the cortical cells indicating that the cells were dieing of apoptosis. Six layers 
of cortical plates were comparably complete, suggesting that cortical lamination was not 
affected. In the lateral ventricle of Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) mice, the 
thickness of the corpus callosum was reduced, and the fimbria of the hippocampus was 
shrunk. Cell loss was apparent in the SVZ and RE, where neural stem cells reside. Cells 
surrounding the lateral ventricle of Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) brains 
appeared to gradually die, making the lateral ventricle larger than that of control littermates 
(Fig. 4-8B and D).  
In the olfactory bulb, hemorrhage usually occurred near the glomerular layer. The 
mitral cell layer in Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) brains was greatly reduced or 
complete absent. Cell loss was also found in the granular cell layer of the olfactory bulb (Fig. 
4-9B and D), the destination of the neural stem cell descendants from the SVZ that migrate 
through RMS while differentiating into granular interneurons (Lois et al., 1996). The cell loss 
in the granular cell layer of olfactory bulb may reflect damage in the SVZ and RE that caused 
fewer migrating cells along the RMS required to replenish cells in the granular cell layer.  By 
contrast, brains from Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice did not show any neurodegeneration 
in their cortex, lateral ventricle or olfactory bulb (Fig. 4-7F, 4-8F and 4-9F). 
TUNEL analysis was performed to confirm that neurodegeneration was due to the 
induction of apoptosis. Sections of cortex and olfactory bulb from Egfrtm1Dwt/tm1Dwt, Nestin-
Cre brains had apoptotic cells lining of the areas of damage in the cortex and were also 
scattered throughout the olfactory bulb (Fig. 4-10B and D). 
 Because of the abnormality in the lateral ventricle of Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and 
Nestin-Cre) brains, it was speculated that there may also be damage or cell death in the 
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choroid plexus, which produces the cerebrospinal fluid (CSF).  The choroid plexus from 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) brains had a less well-organized villi structure. 
Some fibroblasts and collagen fibrils in the connective tissue of villi appeared reduced. The 
fenestrations of the endothelial cells of the capillaries in the connective tissue were not 
distinct. The choroid epithelial cells, which primarily secrete CSF and form a lining covering 
of villi, had less cytoplasm altering the normal cuboidal shape (Fig. 4-11B and D). However, 
the choroid plexus from Egfrtm1Dwt/tm1Dwt, hGFAP-Cre brains did not display any 
morphological change when compared to that from control littermates (Fig. 4-11F).  
 
Overlapping Cre expression from Nestin-Cre and hGFAP-Cre suggests 
neurodegeneration is a secondary effect  
 Since results showed that the neurodegeneration occured in the cortex, olfactory bulb, 
SVZ and RE from Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) mouse brains, but not in the 
brains of Egfrtm1dwt/tm1dwt, hGFAP-Cre mice, Nestin-Cre and hGFAP-Cre mice were crossed 
to the R26R lacZ reporter mice to locate differences in Cre expression driven by Nestin and 
hGFAP promoters. The reporter mice express lacZ only in the presence of Cre recombinase 
(Soriano, 1999). LacZ expression, as detected by X-gal staining, was throughout the entire 
brains of R26R/Nestin-Cre mice (Fig. 4-12B), confirming that Cre is expressed in neural 
stem cells when driven by the Nestin promoter. The R26R/hGFAP-Cre showed an equally 
extensive pattern of X-gal staining (Fig. 4-12B and C; 4-13A-D), which was consistent with 
a report suggesting that the hGFAP-Cre line expresses Cre not only in differentiated glial 
cells but also in neural progenitor cells (Zhuo et al., 2001). In the cerebellum of 
R26R/hGFAP-Cre mice, most cells were positive for X-gal staining except the Purkinje cells; 
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X-gal staining was also scattered throughout the septum, thalamus, hypothalamus, midbrain, 
pons, and medulla (Fig. 4-12C). In addition, cells residing in the SVZ and in the RMS stained 
positive for X-gal (Fig. 4-13F), despite the lack of histological signs of neurodegeneration in 
these areas from Egfrtm1Dwt/tm1Dwt, hGFAP-Cre brains. One clear difference between Cre 
expression in R26R/Nestin-Cre and R26R/hGFAP-Cre brains was in the choroid plexus, 
which showed positive X-gal staining in the R26R/Nestin-Cre brains but negative in 
R26R/hGFAP-Cre brains (Fig. 4-13E and F). 
 
Western blot analysis shows extensive loss of EGFR in Egfrtm1Dwt/tm1Dwt, Sox2-Cre 
(Nestin-Cre, and hGFAP-Cre) brains 
 Western blot analysis was used to verify that the Egfrtm1Dwt allele was converted to the 
Egfr∆ alelle via Cre expression in the brains. The brains were separated into two parts, one 
containing the prosencephalon consisting of the cortex, olfactory bulb, septum, thalamus and 
hypothalamus and the other containing the mesencephalon and rhombencephalon consisting 
of the midbrain, cerebellum, pons and medulla. Both parts from brains of Egfrtm1Dwt/tm1Dwt, 
Sox2-Cre (as well as Nestin-Cre and hGFAP-Cre) mice displayed complete loss of EGFR, 
indicating that the Egfrtm1Dwt allele is disrupted efficiently by all the Cre transgenic lines (Fig. 
4-14A-C). 
 
Discussion 
Egfr null mice develop neurodegeneration in the cortex and olfactory bulb and die 
before weaning, even after placental defects have been rescued. This result raises the 
question of what cell types are affected. To identify the underlying defects, Egfr conditional 
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knockout mice were crossed to three different Cre lines. Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice 
should have Egfr disrupted in the entire neonate, while Egfrtm1Dwt/tm1Dwt, Nestin-Cre should 
result in Egfr disruption throughout the entire brain. Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice 
should have a more restricted disruption of Egfr, being primarily restricted to glial lineages 
including astrocytes, oligodendrocytes and microglias as well as some neurons. The results 
demonstrated that Egfrtm1Dwt/tm1Dwt mice with Sox2-Cre or Nestin-Cre, but not hGFAP-Cre, 
have neurodegeneration in the cortex, olfactory bulb, and growth retardation consistent with 
those from Egfr null mice (Sibilia et al., 1998; Threadgill et al., 1995). Based on these 
results, the likely explanation is that EGFR has a direct impact on neuronal survival. 
However, it has been shown that hGFAP-Cre line not only expresses Cre in glial cells but 
also in precursor cells of the cerebral cortex (Zhuo et al., 2001), the most extensive site of 
neurodegeneration.  
When R26R was used to identify differences between Nestin-Cre and hGFAP-Cre, a 
very similar Cre expression pattern was observed in the cortex and olfactory bulb (Fig. 4-12B 
and C; 4-13A-D) indicating that Cre was not only expressed in the astrocytes but also in the 
neurons by hGFAP. Confirming this result, western blot analysis showed extensive loss of 
EGFR in the cerebral cortex of Egfrtm1Dwt/tm1Dwt, Nestin-Cre as well as Egfrtm1Dwt/tm1Dwt, 
hGFAP-Cre mice. These results suggest that neurodegeneraton in the cortex and olfactory 
bulb of Egfr null mice is not a primary effect of EGFR loss in the dying cells. 
Previous report has suggested that neurodegeneration in the cortex and olfactory bulb 
of Egfr null mice is due to the death of Egfr deficient cortical astrocytes (Wagner et al., 
2006). An in vitro co-culture system was used to show that the increased neuronal death was 
caused by Egfr null cortical astrocytes that no longer provide enough neurotropic support for 
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neuronal survival, whereas Egfr null midbrain astrocytes are not affected and can support 
midbrain neuronal survival. Based on this conclusion, the neurodegenerative phenotype 
should have been evident in Egfrtm1Dwt/tm1Dwt, hGFAP-cre mice since Egfr is disrupted in 
cortical astrocytes. However, Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice did not show the 
neurodegenerative phenotype. Since Cre expression may be incompletely penetrant, raising 
the possibility that there may be enough astrocytes expressing Egfr to secrete sufficient 
neurotrophic factors to support neuronal survival. If this is the case, cell number should be 
reduced in the cortex and olfactory bulb. However, when compared to wildtype mice, no 
detectable reduction in cortical or olfactory bulb cell number was detected in 
Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice. Furthermore, X-gal staining and western blot analysis did 
not support differential Cre expression in the cortex and olfactory bulb from Egfrtm1Dwt/tm1Dwt 
carrying hGFAP-Cre versus Nestin-Cre. Therefore, it is not likely that inefficient Cre 
expression leads to protection from the neurodegenerative phenotype in Egfrtm1Dwt/tm1Dwt, 
hGFAP-Cre mice. 
Abnormalities were also observed in the areas surrounding the lateral ventricle in the 
brains from Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) mice including a reduced thickness 
of the corpus callosum, smaller fimbria of the hippocampus and cell loss in the SVZ and RE, 
thus enlarging the lateral ventricle compared with wildtype mice (Fig. 4-8A-D). The cells 
that reside in the SVZ are mostly astrocytes, which are also neural stem cells that develop 
into neuroblasts and migrate along RMS to the olfactory bulb, where they differentiate into 
granular and periglomerular interneurons (Doetsch et al., 1999; Garcia et al., 2004; Merkle et 
al., 2004). Because of damages in the SVZ and RE, it is not surprising that cell loss was 
observed in the granular layer of olfactory bulb in Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-
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Cre) mice (Fig. 4-9B and D). Although loss of EGFR caused neuronal or astroctic death in 
these areas, this must be secondary since similar cell death was not observed in 
Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice (Fig. 4-8E and F); the data showed that those cells were 
positive for X-gal staining in R26R/hGFAP brains (Fig. 4-13F). If loss of EGFR causes 
neuronal death directly, Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice should display damage in the 
olfactory bulb subsequent to the neural stem cells differentiating into interneurons. Similarly, 
if loss of EGFR directly causes astrocytic death, which in turn led to neuronal death, then 
damage in the SVZ should have been seen in the Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice. 
Based on results presented herein, it is unlikely that cell loss in the cortex, olfactory 
bulb and SVZ is a direct effect from loss of EGFR. Rather, the neurodegeneration occurring 
in Egfrtm1Dwt/tm1Dwt, Sox-Cre (and Nesin-Cre) mice is a secondary effect. Additionally, since 
Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice did not display neurodegeneration in any of the three 
areas primarily affected in the other Cre crosses, the neurodegeneration that does occur in the 
cortex, olfactory bulb and SVZ may result from a common primary event. One possibility 
that connects the three regions is the choroid plexus-cerebrospinal fluid (CP-CSF) system.  
CSF is primarily produced by the choroid plexus (Speake et al., 2001), flowing 
through the ventricular system and into the subarachnoid space; it is eventually absorbed by 
the arachnoid villi and returned to venous circulation (Di Terlizzi and Platt, 2006). The CSF 
serves as a cushion to protect the brain.  Other functions of CSF include protection of the 
brain during blood pressure fluctuation, regulation of the chemical environment of the CNS, 
nutrient transport and detoxification (Di Terlizzi and Platt, 2006; Emerich et al., 2005; 
Redzic and Segal, 2004). It is possible that the neurodegeneration occurring in Egfr null and 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) mice is due to a decrease in secretion of 
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important neuronal surivival factors or neurotrophic factors into the CSF.  A major clue 
pointing toward the choroid plexus is the fact that the choroid plexus in R26R/Nestin-Cre 
mice were positive for X-gal staining, while being negative in R26R/hGFAP-Cre mice (Fig. 
4-13E and F). Additionally, the morphological changes in the choroid plexus epithelium in 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) mice were not observed in Egfrtm1Dwt/tm1Dwt, 
hGFAP-Cre mice (Fig. 4-11A-F). An abnormally functioning choroid plexus may lead to a 
reduced secretion of CSF and/or a decrease in the secretion of nutrients (e.g. glucose, amino 
acids), growth factors (e.g. insulin-like growth factor II, transforming growth factor β), and 
neurotrophic factors (e.g. nerve growth factor [NGF], neurotrophin-4 [NT-4]) (Redzic and 
Segal, 2004; Timmusk et al., 1995). Neurotrophic or growth factors secreted by the choroid 
plexus have been shown to have therapeutic potential. Neurite outgrowth from hippocampal 
neurons is promoted when co-cultured with choroid plexus ependymal cells (Kimura et al., 
2004). Similarly, when the choroid plexus is grafted into the adult rat spinal cord, it can 
promote the growth of regenerating axons in the injured dorsal funiculus (Ide et al., 2001). 
Additionally, encapsulated choroid plexus from neonatal pigs transplanted into rat striatum 
can protect acetyltransferase (ChAT) positive neurons in a rat model of Huntington’s disease 
(Borlongan et al., 2004).  
An abnormal choroid plexus may also cause alteration of the chemical environment 
within the brain. A possible mechanism is through alteration of ionic concentrations, 
especially Na+, Cl-, K+, and Ca2+, leading to depolarization of neurons and an increased 
uptake of Ca2+, which can induce neuronal apoptosis (Mattson, 2006; Mattson et al., 2001). 
Alternatively, impairment of the choroid plexus may increase metal-induced neurotoxicity 
and oxidative stress since one of the functions of the choroid plexus is detoxification. The 
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choroid plexus contains high concentrations of glutathione, cysteine, metallothionein and 
protective enzymes such as superoxide dismutase, glutathione-s-transferase, glutathione 
peroxidase and reductase to sequester heavy metals, metalloid ions such as mercury (Hg), 
Cadium (Cd), Arsenic (As) and free-radical oxidative stresses that are harmful to cells in the 
CNS (Emerich et al., 2005; Zheng, 2001). Growing evidence links the choroid plexus to 
neurodegenerative diseases (e.g. Alzheimer’s and Huntington’s diseases) (Emerich et al., 
2005). More importantly, it has been reported that EGFR is expressed by the choroid plexus 
ependymal cells in the rat, and some ependymal cells are neural progenitor cells (Itokazu et 
al., 2006). 
If neurodegeneration in Egfr null and Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) 
mice is a secondary event, then EGFR signaling is not directly required for neuronal or 
astrocytic survival. However, the loss of EGFR may make neurons or astrocytes more 
sensitive to the alterations in the chemical environment, reduced concentration of growth 
factors or an increase in neurotoxins or oxidative stresses since one function of EGFR is to 
prevent apoptosis. Further studies into the changes in the CSF of Egfr null mice, such as 
measuring ion concentrations may provide insights to whether an abnormally functioning 
choroid plexus leads to neurodegeneration. 
The data collected in this study suggests the possibility of secondary effect for the 
neurodegeneration that occur in Egfr null and Egfrtm1Dwt/tm1Dwt, Sox2-Cre (and Nestin-Cre) 
mice. Elucidation of the mechanism responsible for the neurodegeneration induced by Egfr-
deficiency will provide new insights into the role of EGFR in the brain. 
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Fig. 4-1 Coat phenotypes of Egfr mutnat mice. (A) Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice 
(right two) displayed skin abnormalities and were smaller than their littermates. (B) 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre mouse (right) was smaller than its littermate. (C) 
Normal Egfrtm1Dwt/+, hGFAP-Cre mouse. (D) Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mouse 
displaying a wavy coat. 
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Fig. 4-2 Survival curves of Egfr mutant mice. (A) Survival of Egfrtm1Dwt/tm1Dwt, 
Sox2-Cre mice was significantly lower than he control groups. (B) Survival of 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre mice was significantly lower than control groups. (C) 
No difference in survival between Egftm1Dwt/tm1Dwt, hGFAP-Cre mice and control 
groups. 
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Fig. 4-3 Postnatal growth. (A and B) Female and male Egfrtm1Dwt/tm1Dwt, Nestin-
Cre mice display growth retardation compared to control groups.  
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Fig. 4-4 Post-weaning body weights. (A) Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice 
display growth retardation at weaning (11.05 ± 0.64 vs 13.02 ± 0.56 g, p<0.05 
in female; 11.50 ± 0.74 vs 14.18 ± 0.71 g, p<0.05 in male). (B) Adult wildtype 
and Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice have similar body weights at two 
months of age (21.25 ± 0.58 vs 20.63 ± 0.64 g, p=0.48 in female; 26.86 ± 0.64 
vs 28.37 ± 0.73 g, p=0.14 in male). 
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Fig. 4-5 Full-term body weights. (A-C) Egfrtm1Dwt/tm1Dwt, Sox-Cre 
(Nestin-Cre and hGFAP-Cre) embryos at E18.5 display no 
differences in body weight compared with their control groups. 
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Fig. 4-6 Blood sugar levels. (A) Egfrtm1Dwt/tm1Dwt, Nestin-Cre mice have 
lower blood sugar levels than their controls (65.5 ± 6.5 vs 117.5 ± 6.7 
mg/dl, p<0.001 in female; 67.9 ± 8.4 vs 115.7 ± 6.8 mg/dl, p<0.001 in 
male). (B) Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice have lower blood sugar 
levels than their controls (123.4 ± 4.3 vs 137 ± 3.8 mg/dl, p<0.05 in 
female; 122.8 ± 6.4 vs 140.1 ± 4.1 mg/dl, p<0.05 in male). 
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Fig. 4-7 Cortical histology. (A) Normal Egfrtm1Dwt/+, Sox2-Cre cortex (P8). (B) 
Smaller Egfrtm1Dwt/tm1Dwt, Sox2-Cre cortex with apoptotic cells and bleeding (P8). 
(C) Normal Egfrtm1Dwt/+, Nestin-Cre cortex (P23). (D) Degenerative 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre cortex forming a cavity (P23). (E) Normal 
Egfrtm1Dwt/+, hGFAP-Cre cortex (1M). (F) Normal Egfrtm1Dwt/tm1Dwt, hGFAP-Cre 
cortex (1M). A-F, H&E stains, 50X 
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Fig. 4-8 Ventricular histology. (A) Normal phenotype in the areas surrounding 
the lateral ventricle of Egfrtm1Dwt/+, Sox2-Cre brain (P8). (B) Egfrtm1Dwt/tm1Dwt, 
Sox2-Cre brain displayed neurodegeneration with reduced thickness of corpus 
callosum, reduced fimbria of hippocampus, and cell loss in the SVZ and RE 
(P8). (C) Normal phenotype of Egfrtm1Dwt/+, Nestin-Cre brain in the areas 
surrounding lateral ventricle (P23). (D) Egfrtm1Dwt/tm1Dwt, Nestin-Cre brain 
displayed neurodegeneration with reduced thickness of corpus callosum, reduced 
fimbria of hippocampus, and cell loss in the SVZ and RE (P23). (E) Normal 
phenotype of Egfrtm1Dwt/+, hGFAP-Cre brain in the areas surrounding lateral 
ventricle (1M). (F) Egfrtm1Dwt/tm1Dwt, hGFAP-Cre brain displayed normal 
phenotype in the areas surrounding lateral ventricle (1M). A-F H&E stains, 50X. 
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Fig. 4-9 Olfactory bulb phenotype. (A) Normal Egfrtm1Dwt/+, Sox2-Cre olfactory bulb 
(P8). (B) Egfrtm1Dwt/tm1Dwt, Sox2-Cre olfactory bulb displayed neurodegeneration 
with cell loss of mitral and granular cell layers as well as bleeding near the 
glomerular layer (P8). (C) Normal Egfrtm1Dwt/+, Nestin-Cre olfactory bulb (P23). (D) 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre olfactory bulb displaying neurodegeneration with the 
disappearance of mitral cell layer as well as slight cell loss in the granular cell layer 
(P23). (E) Normal Egfrtm1Dwt/+, hGFAP-Cre olfactory bulb (1M). (F) 
Egfrtm1Dwt/tm1Dwt, hGFAP-Cre olfactory bulb showing no sign of neurodegeneration 
(1M). A-F H&E stains, 50X. 
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Fig. 4-10 TUNEL analysis. (A) Egfrtm1Dwt/+, Nestin-Cre cortex displayed almost no 
apoptotic cells. (B) Egfrtm1Dwt/tm1Dwt, Nestin-Cre cortex with apoptotic cells (brown 
spots) lining the border of the cavity caused by the neurodegenration. (C) 
Egfrtm1Dwt/+, Nestin-Cre olfactory bulb displaying almost no apoptotic cells. (D) 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre olfactory bulb displaying many apoptotic cells 
throughout the olfactory bulb. A-D 50X. 
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Fig. 4-11 Choroid plexus histology. (A) Normal Egfrtm1Dwt/+, Sox2-Cre choroid 
plexus (P8). (B) Egfrtm1Dwt/tm1Dwt, Sox2-Cre choroid plexus displaying less intact 
structure with loss of fibroblasts and collagen fibrils in the connective tissue of 
the villi (P8). (C) Normal Egfrtm1Dwt/+, Nestin-Cre choroid plexus (P23). (D) 
Egfrtm1Dwt/tm1Dwt, Nestin-Cre choroid plexus displaying abnormal shape with less 
cytoplasm in the choroid epithelial cells (P23). (E) Normal Egfrtm1Dwt/+, hGFAP-
Cre choroid plexus (1M). (F) Egfrtm1Dwt/tm1Dwt, hGFAP-Cre choroid plexus did 
not display any abnormality (1M). A-F H&E stains, 200X. 
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Fig. 4-12 Reporter X-gal staining. (A) R26R brain was negative for X-gal 
staining indicating no endogenous lacZ activity. (B) R26R/Nestin-Cre brain 
displaying extensive positive X-gal staining in the whole brain. (C) 
R26R/hGFAP-Cre brain displaying extensive X-gal staining in the cortex, 
olfactory bulb as well as cerebellum, and scattered X-gal staining 
throughout the septum, thalamus, hypothalamus, midbrain, pons and 
medulla. A-C 15X. 
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Fig. 4-13 Comparison of reporter X-gal staining. (A) R26R/Nestin-Cre cortex 
with X-gal staining. (B) R26R/hGFAP-Cre cortex with X-gal staining. (C) 
R26R/Nestin-Cre olfactory bulb with X-gal staining. (D) R26R/hGFAP olfactory 
bulb with X-gal staining. (E) R26R/Nestin-Cre choroid plexus with positive X-
gal staining. (F) R26R/hGFAP-Cre brain displaying positive X-gal staining in 
the SVZ (white arrow) and RMS, but negative in the choroid plexus (black 
arrow). A-D 50X. E-F 100X. 
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Fig. 4-14 Western blot analysis for EGFR expression. (A-C) Western blot analysis 
displaying the loss of EGFR in Egfrtm1Dwt/tm1Dwt, Sox2-Cre (Nestin-Cre and hGFAP-Cre) 
brains. Egfrtm1Dwt/tm1Dwt, Sox2-Cre (Nestin-Cre and hGFAP-Cre) brains were separated into 
two parts (prosencephalon and mesencephalon + rhombenphalon).  
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Gene targeting technology is a powerful tool to study gene function in mouse models. 
Constitutional knockout of Egfr in mice results in placental defects with mice dying pre- or 
perinatally. This limits the study of EGFR in later stages of development or physiological 
functions in adults. Thus, the generation of an Egfr conditional allele was needed to 
overcome this limitation. The Egfr conditional allele, Egfrtm1Dwt, possessed wildtype function 
since Egfrtm1Dwt/- mice were viable, fertile and did not display any detectable abnormal 
phenotype. The EgfrΔ allele, resulting from EIIa-Cre-mediated inactivation of Egfr by 
deletion of exon 3, was confirmed to function as a null allele by demonstrating that EgfrΔ/Δ 
embryos on a 129,B6 mixed genetic background die at midgestation due to placental defect 
identical to that of Egfr null embryos. In order to analyze EGFR function within the brain, 
three Cre transgenic lines (Sox2-Cre, Nestin-Cre, hGFAP-Cre) were used. Egfrtm1Dwt/tm1Dwt, 
Sox2-Cre, as well as Nestin-Cre and hGFAP-Cre, mice were generated. Only 
Egfrtm1Dwt/tm1Dwt, Sox2-Cre and Nestin-Cre mice displayed neurodegeneration similar to Egfr 
null mice surviving to birth, while Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice did not show any 
neurodegeneration. This result confirms that neurodegeneration is independent of placental 
defects, and is the major cause of postnatal lethality in mice lacking EGFR. In the current 
study, the data also suggests that neurodegeneration is a secondary effect. However, we can 
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not completely rule out the possibility that EGFR signaling is directly required for neuronal 
or astrocytic survival. Therefore, it will be necessary to use neuron-specific and astrocyte-
specific Cre lines in future studies. The data suggests that the choroid plexus is a potential 
cause of the neurodegeneration, thus examination of CSF composition would be a promising 
avenue for additional studies. 
The current study not only presents the necessity of EGFR within the brain, but also 
presents new mouse models that can be used as a platform for exploring other EGFR 
functions in vivo. Nearly 20% of Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice survive for more than one 
month due to mosaic deletion of Egfr. Some of the surviving mice have been examined but 
showed no overt neurodegeneration supporting neurodegeneration as a likely cause for 
postnatal lethality in Egfr null mice. Although the surviving mice did not display an obvious 
neurodegenerative phenotype, they may be a valuable model for examining possible 
phenotypes developing in other tissues since Egfrtm1Dwt/tm1Dwt, Sox2-Cre mice possess no or 
very low EGFR activity in all tissues. Likewise, surviving Egfrtm1Dwt/tm1Dwt, Nestin-Cre and 
hGFAP-Cre mice can be used in other studies. Although these mice did not display a 
neurodegenerative phenotype, they did nonetheless show growth retardation at early 
postnatal stages. Additional experiments have been performed feeding Egfrtm1Dwt/tm1Dwt, 
hGFAP-Cre mice between 12-14 weeks of age a high fat diet for 3 months. The mean weight 
gain of Egfrtm1Dwt/tm1Dwt, hGFAP-Cre mice was significantly lower than that of 
Egfrtm1Dwt/tm1Dwt control mice. Therefore, surviving Egfrtm1Dwt/tm1Dwt, Nestin-Cre and hGFAP-
Cre mice may be good models for investigating a role for EGFR in metabolism.  
The Egfr conditional mouse model should also be a good platform for cancer 
research. Many types of cancers overexpress EGFR leading to proliferation, survival and 
 102 
metastasis, and EGFR is a recognized therapeutic target for cancer treatment. Thus, by 
combining mouse cancer models with the Egfr conditional model, the role of EGFR in cancer 
biology can be evaluated to develop better strategies for cancer treatment. For example, 
EGFR is a therapeutic target for the treatment of colorectal cancer. However, clinically there 
are still at least 20% of colorectal cancers do not express EGFR, which means that those 
cancer cells may not rely on EGFR signaling. Other studies have used the ApcMin mouse 
model for colorectal cancer in combination with tissue-specific deletion of Egfr in the 
epithelial cells of intestine using the Villin-Cre transgene. ApcMin, Egfrtm1Dwt/tm1Dwt, Villin-Cre 
mice display a significant reduction in polyp number reconfirming the importance of EGFR 
signaling for colorectal cancer development. These mice also provide an opportunity to 
examine polyps in which EGFR signaling is not necessary for development, and to identify 
compensatory signaling pathways that may be used by colorectal cancers lacking EGFR. 
More importantly, this should support new strategies for the treatment of colorectal cancer. 
As EGFR is a major regulator of cellular signals, there is good reason to believe that 
EGFR has many unexplored functions. The Egfr condtional allele described herein will be a 
powerful tool to unravel other EGFR functions. As the reservoir of Cre lines increases, 
knowledge about EGFR function within specific cell types or tissues can be expanded. 
 
 
